



**EFSA ; Scientific Opinion on Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1): Consideration of aliphatic and aromatic amines and amides evaluated by JECFA (65th meeting)**

**EFSA Publication**

*Link to article, DOI:*  
[10.2903/j.efsa.2011.1926](https://doi.org/10.2903/j.efsa.2011.1926)

*Publication date:*  
2011

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
EFSA Publication (2011). *EFSA ; Scientific Opinion on Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1): Consideration of aliphatic and aromatic amines and amides evaluated by JECFA (65th meeting)*. European Food Safety Authority. EFSA Journal No. 1926 <https://doi.org/10.2903/j.efsa.2011.1926>

---

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## SCIENTIFIC OPINION

### Scientific Opinion on Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1):

### Consideration of aliphatic and aromatic amines and amides evaluated by JECFA (65<sup>th</sup> meeting)<sup>1</sup>

### EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)<sup>2, 3</sup>

European Food Safety Authority (EFSA), Parma, Italy

#### SUMMARY

The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the implications for human health of chemically defined flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and its consecutive amendments.

The present consideration concerns 34 aliphatic and aromatic amines and amides evaluated by the JECFA (65<sup>th</sup> meeting). The Panel concluded that no corresponding FGE is available.

Further two substances were evaluated by the JECFA in this group, but these are not in the Register (1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, respectively). A third substance evaluated by the JECFA is an alpha,beta-unsaturated ketone [FL-no: 14.168] considered with respect to genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19, for which a final conclusion regarding its genotoxic properties could not be reached and additional data were requested. This consideration therefore only deals with 34 flavouring substances.

---

1 On request from the Commission, Question No EFSA-Q-2010-01261, adopted on 25 November 2010.

2 Panel members: Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef Wölflle. [CEF-unit@efsa.europa.eu](mailto:CEF-unit@efsa.europa.eu)

3 Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA's staff member Kim Rygaard Nielsen for the preparatory work on this scientific Opinion.

Suggested citation: EFSA ; Scientific Opinion on Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1): Consideration of aliphatic and aromatic amines and amides evaluated by JECFA (65<sup>th</sup> meeting). EFSA Journal 2011; 9(4):1926. [42 pp.]. doi:10.2903/j.efsa.2011.1926. Available online: [www.efsa.europa.eu/efsajournal.htm](http://www.efsa.europa.eu/efsajournal.htm)

The Panel agreed with the application of the Procedure as performed by the JECFA for 27 of the 34 substances. The JECFA concluded on five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] at step B4, but the Panel did not agree that appropriate studies are available for deriving NOAELs and accordingly the Panel in FGE.86 concluded that additional toxicity data are required for these five substances.

The flavouring Industry has in response to the requested toxicity data in FGE.86 submitted additional data for three of the five substances [FL-no: 16.091, 16.093 and 16.094]. The following information has been submitted:

Ames test and acute oral toxicity test have been submitted by Industry on [FL-no: 16.093]. The Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 16.094]. These studies do not fulfil the suggested minimum requirement to provide an adequate NOAEL for flavourings in the Procedure, which is considered to be a 90-day study. The minimum requirement has not been met by the new toxicity data submitted by Industry for the substances in FGE.86 therefore additional toxicity data is still requested.

Further has Industry submitted Ames test and a 28 day study on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094]. The Panel did not consider [FL-no: 16.095] sufficiently structurally related to be used as supporting substance for this FGE.

In addition to the five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] for which the Panel did not agree that appropriate studies are available for deriving NOAELs, butyramide [FL-no: 16.049] cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicity. For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel concluded that this substance can be metabolised to innocuous products and accordingly evaluated along the A-side of the Procedure (while the JECFA evaluated [FL-no: 11.017] along the B-side). Like the JECFA the Panel concluded that [FL-no: 11.017] is of no safety concern at estimated level of intake, based on the MSDI approach. So, the Panel did not agree with the application of the Procedure as performed by the JECFA for 7 of the 34 substances.

For 22 substances evaluated by the JECFA through the Procedure use levels have been provided by the Industry [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 16.094]. The mTAMDI figures calculated for the substances in structural class I are 340 microgram/person/day, except for [FL-no: 16.092], for which the mTAMDI is 15000 microgram/person/day, exceeding the threshold of 1800 microgram/person/day for structural class I. The mTAMDI figures for the structural class II substances range from 200 to 340 microgram/person/day, except for [FL-no: 14.141] for which the figure is 600 microgram/person/day, exceeding the threshold of 540 microgram/person/day for structural class II. For the substances [FL-no: 11.014, 16.052, 16.091, 16.093 and 16.094] in structural class III the figures range from 200 to 1900 microgram/person/day, exceeding the threshold of concern of 90 microgram/person/day for structural class III. Thus, for seven substances [FL-no: 11.014, 14.141, 16.052, 16.091, 16.092, 16.093 and 16.094] the intakes, estimated on the basis of the mTAMDI approach, exceed the threshold for their structural classes. Therefore more reliable exposure data are required. On the basis of such additional data, these flavouring substances should be considered using the Procedure. Subsequently, additional data might become necessary.

For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDI in order to identify those flavouring substances that need more refined exposure assessment and to finalise the evaluation.

In order to determine whether the conclusion for the 34 JECFA evaluated substances can be applied to the materials of commerce, it is necessary to consider the available specifications. Specifications

including complete purity criteria and identity are available for 33 of the 34 JECFA evaluated substances. For one substance [FL-no: 16.013] information on the stereoisomeric composition is lacking.

Thus, for one substance [FL-no: 16.013] the Panel has reservation (information on stereoisomeric composition is requested).

For seven of the 34 evaluated substances the Panel did not agree with the JECFA application of the Procedure and additional toxicity data are required for five of the seven substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094]. One substance cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicity [FL-no: 16.049] and one substance [FL-no: 11.017] is evaluated along the A-side, while the JECFA evaluated it along the B-side.

Overall, for 27 of the 34 JECFA evaluated aliphatic and aromatic amines and amides [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 16.052, 16.053 and 16.092] the Panel agreed with the JECFA conclusion “no safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach.

© European Food Safety Authority, 2011

## **KEY WORDS**

Flavourings, safety, aliphatic amines, aliphatic amides, aromatic amines, JECFA, 65<sup>th</sup> meeting.

## TABLE OF CONTENTS

|  |    |
|--|----|
| Summary .....  | 1  |
| Table of contents .....  | 4  |
| Background .....   | 5  |
| Terms of reference .....   | 5  |
| Assessment .....   | 5  |
| History of the Evaluation of the Substances in the present FGE .....   | 7  |
| 1. Presentation of the Substances in the JECFA Flavouring Group .....  | 8  |
| 1.1. Description .....   | 8  |
| 1.1.1. JECFA Status .....  | 8  |
| 1.1.2. EFSA Considerations .....   | 8  |
| 1.2. Isomers .....   | 8  |
| 1.2.1. JECFA Status .....  | 8  |
| 1.2.2. EFSA Considerations .....   | 8  |
| 1.3. Specifications .....  | 8  |
| 1.3.1. JECFA Status .....  | 8  |
| 1.3.2. EFSA Considerations .....   | 9  |
| 2. Intake Estimations .....  | 9  |
| 2.1. JECFA Status .....  | 9  |
| 2.2. EFSA Considerations .....   | 9  |
| 3. Genotoxicity Data .....   | 11 |
| 3.1. Genotoxicity Studies – Text Taken from the JECFA (JECFA, 2006d) .....                                     | 11 |
| 3.2. EFSA Considerations .....   | 13 |
| 4. Application of the Procedure .....  | 13 |
| 4.1. Application of the Procedure to 34 Aliphatic and Aromatic Amines and Amides by JECFA (JECFA, 2006d) ..... | 13 |
| 4.2. EFSA Considerations .....   | 16 |
| 5. Conclusion .....  | 18 |
| Table 1: Specification Summary .....   | 20 |
| Table 2: Genotoxicity Data .....   | 24 |
| Table 3: Summary of Safety Evaluations .....   | 30 |
| References .....   | 35 |
| Abbreviations .....  | 41 |

## BACKGROUND

Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a Procedure for the establishment of a list of flavouring substances, the use of which will be authorised to the exclusion of all other substances in the EU. In application of that Regulation, a Register of flavouring substances used in or on foodstuffs in the Member States was adopted by Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical groups. Substances within a group should have some metabolic and biological behaviour in common.

Substances which are listed in the Register are to be evaluated according to the evaluation programme laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the Opinion of the Scientific Committee on Food (SCF, 1999a).

Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is necessary.

In the period 2000 – 2008, during its 55<sup>th</sup>, 57<sup>th</sup>, 59<sup>th</sup>, 61<sup>st</sup>, 63<sup>rd</sup>, 65<sup>th</sup>, 68<sup>th</sup> and 69<sup>th</sup> meetings, the JECFA evaluated about 1000 substances, which are in the EU Register.

## TERMS OF REFERENCE

EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted by Commission Decision (EC) No 1999/217 EC (EC, 1999a) and its consecutive amendments.

In addition, in letter of 19 May 2009 the Commission requested EFSA to carry out a re-evaluation of flavouring substances [FL-no: 16.091, 16.093 and 16.094] in accordance with Commission Regulation (EC) No 1565/2000:

“The European Commission requests the European Food Safety Authority to carry out a risk assessment on 2,4-Decadienamide, N-(2-methylpropyl)-, (2E,4E)- ([FL-no: 16.091]), N-Cyclopropyl (2E,6Z)-nonadienamide ([FL-no: 16.093]) and N-Ethyl (2E,6Z)-nonadienamide ([FL-no: 16.094]) in accordance with Commission Regulation (EC) No 1565/2000, if possible by the end of the evaluation programme, if not within nine month from finalisation of that programme”.

The deadline of the Terms of Reference was negotiated to 31 December 2010.

## ASSESSMENT

The approach used by EFSA for safety evaluation of flavouring substances is referred to in Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has been derived from the evaluation Procedure developed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the “JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring

substances are of no safety concern at their estimated levels of intake, whether additional data are required or whether certain substances should not be put through the EFSA Procedure.

The following issues are of special importance.

#### *Intake*

In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) approach to estimate the *per capita* intakes of the flavouring substances in Europe.

In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both European and USA production figures. The highest of the two MSDI figures is used in the evaluation by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of these figures. For Register substances for which this is the case the Panel will need EU production figures in order to finalise the evaluation.

When the Panel examined the information provided by the European Flavour Industry on the use levels in various foods, it appeared obvious that the MSDI approach in a number of cases would grossly underestimate the intake by regular consumers of products flavoured at the use level reported by the Industry, especially in those cases where the annual production values were reported to be small. In consequence, the Panel had reservations about the data on use and use levels provided and the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65<sup>th</sup> meeting considered “how to improve the identification and assessment of flavouring agents, for which the MSDI estimates may be substantially lower than the dietary exposures that would be estimated from the anticipated average use levels in foods” (JECFA, 2006c).

In the absence of more accurate information that would enable the Panel to make a more realistic estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” (mTAMDI) approach based on the normal use levels reported by Industry.

As information on use levels for the flavouring substances has not been requested by the JECFA or has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on use levels in order to finalise the evaluation.

#### *Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA*

The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation Procedure:

“The Committee noted that this value was based on a risk analysis of known carcinogens which involved several conservative assumptions. The use of this value was supported by additional information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the Committee, flavouring substances for which insufficient data are available for them to be evaluated using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per person per day would not be expected to present a safety concern. The Committee recommended that the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended to include the last step on the right-hand side of the original procedure (“Do the condition of use result in an intake greater than 1.5 microgram per day?”) (JECFA, 1999b).

In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does not make use of this threshold of 1.5 microgram per person per day.

#### *Genotoxicity*



As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a possible genotoxic potential of the flavouring substances or of structurally related substances. Generally, substances for which the Panel has concluded that there is an indication of genotoxic potential *in vitro*, will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. Substances for which a genotoxic potential *in vivo* has been concluded, will not be evaluated through the Procedure.

### *Specifications*

Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of JECFA, since the Panel requests information on e.g. isomerism.

### *Structural Relationship*

In the consideration of the JECFA evaluated substances, the Panel will examine the structural relationship and metabolism features of the substances within the flavouring group and compare this with the corresponding FGE.

## **HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE**

In FGE.86, which considered 35 aliphatic and aromatic amines and amides, the Panel concluded that for five substances no applicable NOAEL was available for the substance itself or for a structurally related substance and accordingly further data are required.

| <b>FGE</b> | <b>Opinion adopted by EFSA</b> | <b>Link</b>   | <b>No. of candidate substances</b> |
|------------|--------------------------------|---|------------------------------------|
| 86         | 22 May 2008                    | <a href="http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902197654.htm">http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902197654.htm</a> | 35                                 |
| 86Rev1     | 25 November 2010               |   | 34                                 |

The present Revision of Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1) concerns the re-consideration of three JECFA-evaluated substances considered in FGE.86.

Additional data (Ames test, acute oral toxicity test) have been submitted by Industry on [FL-no: 16.093]. The Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 16.094].

Further has Industry submitted additional data (Ames test and a 28 day study) on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094].

Industry has also submitted additional information needed on stereoisomeric composition [FL-no: 16.013], composition of mixture [FL-no: 11.017], specifications (data on solubility [FL-no: 14.064 and 14.168]), missing ID-tests [FL-no: 11.017, 14.168 and 16.094] and EU production figures [FL-no: 11.006 and 16.053].

[FL-no: 14.168], which contains an alpha,beta-unsaturated ketone structure has been withdrawn from this consideration and transferred to FGE.223 for evaluation with respect to genotoxic potential.

After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated intake was originally based on anticipated poundage data (JECFA, 2009c), but for which new tonnage data were submitted to the JECFA by Industry. These new tonnage figures are included in the present FGE for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052].



Furthermore in FGE.86 two substances [FL-no: 11.006 and 16.053] could not be evaluated using the Procedure, as no EU production figures were available. In February 2010, the Industry provided EU production figures for these two substances together with similar data on approximately 100 other substances from 27 different FGEs. In order to avoid unnecessary delay, these substances were evaluated in FGE.96 (EFSA, 2010aj). The outcome of the evaluations have also been included in the current revision of FGE.86.

## **1. Presentation of the Substances in the JECFA Flavouring Group**

### **1.1. Description**

#### **1.1.1. JECFA Status**

The JECFA has evaluated a group of 37 flavouring substances consisting of aliphatic and aromatic amines and amides at the 65<sup>th</sup> meeting (JECFA, 2006d).

#### **1.1.2. EFSA Considerations**

Two of the 37 flavouring substances evaluated by the JECFA in the group named “aliphatic and aromatic amines and amides” are not in the Register (1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, respectively). A third substance evaluated by the JECFA contains an alpha,beta-unsaturated ketone moiety and has been considered with respect to genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19 (EFSA, 2008b), for which a final conclusion regarding its genotoxic properties could not be reached and additional data were requested. This consideration therefore only deals with 34 flavouring substances.

The Panel concluded that no corresponding FGE is available.

### **1.2. Isomers**

#### **1.2.1. JECFA Status**

The following six substances [FL-no: 11.005, 11.014, 11.020, 14.133, 16.013 and 16.092] in the group of JECFA evaluated aliphatic and aromatic amines and amides have one or more chiral centres. Four substances [FL-no: 14.003, 16.091, 16.093 and 16.094] can exist as geometrical isomers.

#### **1.2.2. EFSA Considerations**

In FGE.86, information is lacking about stereoisomerism for one substance [FL-no: 16.013]. After publication of FGE.86, Industry has informed that it is a mixture of diastereoisomers (EFFA, 2010a). However, information on the ratios of the diastereoisomers is needed. See Table 1.

### **1.3. Specifications**

#### **1.3.1. JECFA Status**

The JECFA specifications are available for all 34 substances (JECFA, 2005d). See Table 1.

### 1.3.2. EFSA Considerations

The available specifications are considered adequate for 33 substances. For one substance [FL-no: 16.013] additional information on the stereoisomeric mixture is needed (See Section 1.2).

## 2. Intake Estimations

### 2.1. JECFA Status

For all 34 substances evaluated through the JECFA Procedure intake data are available for the EU. (See Table 3.1).

After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated intake was originally based on anticipated poundage data (JECFA, 2009c), but for which new tonnage (production) data were submitted to the JECFA by Industry. These new tonnage figures are included in the present FGE for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052].

### 2.2. EFSA Considerations

For seven substances [FL-no: 11.006, 14.167, 16.053, 16.091, 16.092, 16.093 and 16.094] the Industry has submitted production figure for EU to EFSA (EFFA, 2004ao; Flavour Industry, 2004e; Flavour Industry, 2004f). These data have been used in this consideration (see Table 2.2.2 and 3.1).

New tonnage (production) figures are included in the present FGE for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052] (See Section 2.1).

For 22 substances [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 16.094], the Industry has submitted use levels for normal and maximum use (EFFA, 2005c; Flavour Industry, 2004f; EFFA, 2007a) (see Table 2.2.1). Based on these normal use levels mTAMDI figures can be calculated (see Table 2.2.2), (EFSA, 2004d).

**Table 2.2.1 Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.86**

| FL-no  | Food Categories            |            |          |          |        |        |          |         |          |          |        |        |            |          |        |        |        |          |
|--------|----------------------------|------------|----------|----------|--------|--------|----------|---------|----------|----------|--------|--------|------------|----------|--------|--------|--------|----------|
|        | Normal use levels (mg/kg)  |            |          |          |        |        |          |         |          |          |        |        |            |          |        |        |        |          |
|        | Maximum use levels (mg/kg) |            |          |          |        |        |          |         |          |          |        |        |            |          |        |        |        |          |
|        | 01.0                       | 02.0       | 03.0     | 04.1     | 04.2   | 05.0   | 06.0     | 07.0    | 08.0     | 09.0     | 10.0   | 11.0   | 12.0       | 13.0     | 14.1   | 14.2   | 15.0   | 16.0     |
| 11.002 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.004 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.005 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.007 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 1<br>5   | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.014 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.015 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.016 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.018 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.020 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.021 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.023 | 0,4<br>2                   | 0,1<br>0,5 | 0,4<br>2 | 0,4<br>2 | -<br>- | 1<br>5 | 0,2<br>1 | 2<br>10 | 0,2<br>1 | 0,2<br>1 | -<br>- | -<br>- | 0,1<br>0,5 | 0,2<br>1 | -<br>- | 1<br>5 | 1<br>5 | 0,2<br>1 |
| 11.025 | 0,4                        | 0,1        | 0,4      | 0,4      | -      | 1      | 0,2      | 2       | 0,2      | 0,2      | -      | -      | 0,1        | 0,2      | -      | 1      | 1      | 0,2      |

**Table 2.2.1 Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.86**

| FL-no  | Food Categories            |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|--------|----------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|        | Normal use levels (mg/kg)  |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|        | Maximum use levels (mg/kg) |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|        | 01.0                       | 02.0 | 03.0 | 04.1 | 04.2 | 05.0 | 06.0 | 07.0 | 08.0 | 09.0 | 10.0 | 11.0 | 12.0 | 13.0 | 14.1 | 14.2 | 15.0 | 16.0 |
| 11.026 | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 10   | 1    | 1    | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
|        | 0,4                        | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 2    | 0,2  | 0,2  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 10   | 1    | 1    | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 14.080 | 0,4                        | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 2    | 0,2  | 0,2  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 10   | 1    | 1    | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 14.133 | 0,4                        | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 2    | 0,2  | 0,2  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 10   | 1    | 1    | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 14.141 | 4                          | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 2    | 0,2  | 0,2  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 10   | 1    | 1    | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 16.049 | 0,4                        | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 1    | 0,1  | 0,1  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 5    | 0,4  | 0,4  | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 16.052 | 0,4                        | 0,1  | 0,4  | 0,4  | -    | 1    | 0,2  | 1    | 0,1  | 0,1  | -    | -    | 0,1  | 0,2  | -    | 1    | 1    | 0,2  |
|        | 2                          | 0,5  | 2    | 2    | -    | 5    | 1    | 5    | 0,4  | 0,4  | -    | -    | 0,5  | 1    | -    | 5    | 5    | 1    |
| 16.091 | 0,02                       | 0,02 | 0,2  | -    | -    | 2    | -    | 0,2  | 0,02 | 0,02 | -    | -    | 0,02 | -    | 2    | 2    | 0,02 | 0,02 |
|        | 1                          | 1    | 10   | -    | -    | 100  | -    | 10   | 1    | 1    | -    | -    | 1    | -    | 100  | 100  | 1    | 1    |
| 16.092 | 0,4                        | 0,4  | 0,4  | -    | -    | 40   | -    | 4    | 0,4  | 0,4  | -    | -    | 0,4  | -    | 40   | 40   | 0,4  | 0,4  |
|        | 4                          | 4    | 4    | -    | -    | 400  | -    | 40   | 4    | 4    | -    | -    | 4    | -    | 400  | 400  | 4    | 4    |
| 16.093 | 0,05                       | 0,05 | 0,5  | -    | -    | 5    | 1    | 0,5  | 0,05 | 0,05 | -    | -    | 0,05 | -    | 5    | 5    | 0,05 | 0,05 |
|        | 0,5                        | 0,5  | 5    | -    | -    | 50   | 10   | 5    | 0,5  | 0,5  | -    | -    | 0,5  | -    | 50   | 50   | 0,5  | 0,5  |
| 16.094 | 0,05                       | 0,05 | 0,5  | -    | -    | 5    | 1    | 0,5  | 0,05 | 0,05 | -    | -    | 0,05 | -    | 5    | 5    | 0,05 | 0,05 |
|        | 0,5                        | 0,5  | 5    | -    | -    | 50   | 10   | 5    | 0,5  | 0,5  | -    | -    | 0,5  | -    | 50   | 50   | 0,5  | 0,5  |

**Table 2.2.2 Estimated intakes based on the MSDI approach and the mTAMDI approach**

| FL-no  | EU Register name                                    | MSDI – EU<br>(µg/capita/day) | MSDI – USA<br>(µg/capita/day) | mTAMDI<br>(µg/person/day) | Structural<br>class | Threshold of concern<br>(µg/person/day) |
|--------|---|------------------------------|-------------------------------|---------------------------|---------------------|---|
| 11.001 | 3-Methylbutylamine                                  | 24                           | 0.07                          |                           | Class I             | 1800                                    |
| 11.002 | Isobutylamine                                       | 0.012                        | 0.09                          | 340                       | Class I             | 1800                                    |
| 11.003 | Butylamine  | 89                           | 0.01                          |                           | Class I             | 1800                                    |
| 11.004 | Propylamine   | 0.012                        | 0.02                          | 340                       | Class I             | 1800                                    |
| 11.005 | sec-Butylamine                                      | 0.012                        | 2                             | 340                       | Class I             | 1800                                    |
| 11.009 | Trimethylamine                                      | 130                          | 70                            |                           | Class I             | 1800                                    |
| 11.015 | Ethylamine  | 0.012                        | 0.2                           | 340                       | Class I             | 1800                                    |
| 11.016 | Hexylamine  | 0.024                        | 0.007                         | 340                       | Class I             | 1800                                    |
| 11.018 | Isopropylamine                                      | 0.012                        | 0.02                          | 340                       | Class I             | 1800                                    |
| 11.020 | 2-Methylbutylamine                                  | 0.012                        | 0.02                          | 340                       | Class I             | 1800                                    |
| 11.021 | Pentylamine   | 0.037                        | 0.2                           | 340                       | Class I             | 1800                                    |
| 11.023 | Triethylamine                                       | 0.073                        | 0.9                           | 340                       | Class I             | 1800                                    |
| 11.025 | Trimethylamine oxide                                | 2.3                          | 0.09                          | 340                       | Class I             | 1800                                    |
| 11.026 | Tripropylamine                                      | 0.012                        | 0.02                          | 340                       | Class I             | 1800                                    |
| 16.092 | N,N-Dimethyl menthyl succinamide                    | 61                           | 88                            | 15000                     | Class I             | 1800                                    |
| 11.006 | Phenethylamine                                      | 0.075                        | 0.05                          |                           | Class II            | 540                                     |
| 11.007 | 2-(4-Hydroxyphenyl)ethylamine                       | 0.012                        | 0.02                          | 340                       | Class II            | 540                                     |
| 14.010 | Piperidine  | 88                           | 96                            |                           | Class II            | 540                                     |
| 14.064 | Pyrrolidine   | 0.12                         | 2                             |                           | Class II            | 540                                     |
| 14.080 | 2-Acetyl-1-pyrroline                                | 0.012                        | 0.1                           | 340                       | Class II            | 540                                     |
| 14.133 | 2-Methylpiperidine                                  | 0.012                        | 0.002                         | 340                       | Class II            | 540                                     |
| 14.141 | Piperazine  | 0.012                        | 0.002                         | 600                       | Class II            | 540                                     |
| 14.167 | 1-Pyrroline   | 0.012                        | 0.4                           |                           | Class II            | 540                                     |
| 16.049 | Butyramide  | 0.012                        | 0.002                         | 200                       | Class II            | 540                                     |
| 16.013 | N-Ethyl-2-isopropyl-5-methylcyclohexane carboxamide | 0.4                          | 127                           |                           | Class III           | 90                                      |
| 16.053 | 2-Isopropyl- N,2,3-trimethylbutanamide              | 24                           | 1054                          |                           | Class III           | 90                                      |
| 11.014 | N,N-Dimethylphenethylamine                          | 0.012                        | 0.09                          | 340                       | Class III           | 90                                      |
| 11.017 | N-Isopentylidene isopentylamine                     | 0.012                        | 0.01                          |                           | Class III           | 90                                      |
| 14.003 | Piperine  | 20                           | 0.07                          |                           | Class III           | 90                                      |
| 16.006 | N-Nonanoyl 4-hydroxy-3-methoxybenzylamide           | 6.0                          | 0.07                          |                           | Class III           | 90                                      |
| 16.052 | 1,6-Hexalactam                                      | 0.012                        | 0.002                         | 200                       | Class III           | 90                                      |
| 16.091 | Deca-(2E,4E)-dienoic acid isobutylamide             | 6.1                          | 83                            | 770                       | Class III           | 90                                      |
| 16.093 | N-Cyclopropyl (2E,6Z)-nonadienamide                 | 61                           | 40                            | 2000                      | Class III           | 90                                      |
| 16.094 | N-Ethyl (2E,6Z)-nonadienamide                       | 61                           | 88                            | 2000                      | Class III           | 90                                      |

### 3. Genotoxicity Data

#### 3.1. Genotoxicity Studies – Text Taken<sup>4</sup> from the JECFA (JECFA, 2006d)

##### *In vitro*

No mutagenicity was found in the standard Ames assay when various strains of *Salmonella typhimurium* (TA97a, TA98, TA100, TA102, TA1535, TA1537, TA1538, TA1530, TA1531, TA1532 and TA1964) were incubated with up to 10000 microgram/plate of ethylamine [FL-no: 11.015], isopropylamine [FL-no: 11.018], butylamine [FL-no: 11.003], isobutylamine [FL-no: 11.002], pentylamine [FL-no: 11.021], acetamide (No. 1592, not in Register), 2-isopropyl-N,2,3-trimethylbutyramide [FL-no: 16.053], N-isobutyl (E,E)-2,4-decadienamide [FL-no: 16.091], piperine [FL-no: 14.003], piperidine [FL-no: 14.010], pyrrolidine [FL-no: 14.064], trimethylamine [FL-no: 11.009], triethylamine [FL-no: 11.023] or piperazine [FL-no: 14.141] with or without metabolic activation (Green & Savage, 1978; Haworth et al., 1978; Andrews et al., 1980; Florin et al., 1980; Haworth et al., 1983; Mortelmans et al., 1986; Zeiger et al., 1987; Karekar et al., 1996; King, 2003).

In a host-mediated assay in which *S. typhimurium* strain TA1950, TA1951, TA1952 or TA1964 was injected intraperitoneally into mice followed by an intramuscular injection of 800 mg/kg bw of piperidine or pyrrolidine, no mutagenicity was observed (Green & Savage, 1978).

There was no evidence of DNA damage when *Escherichia coli* 343/591 uvrB-/recA-/lac+ or uvrB+/recA+/lac+ was incubated with up to 1080 mM (63793 microgram/ml) of acetamide (No. 1592, not in Register) or up to 33.7 mM (2870 microgram/ml) of piperidine [FL-no: 14.010] (Hellmér & Bolcsfoldi, 1992a). In the SOS Chromotest with *E. coli* PQ37, the N-nitroso derivative of tyramine [FL-no: 11.007] gave positive results (Ohshima et al., 1989).

Assays in mammalian cell lines have been performed with tyramine [FL-no: 11.007], acetamide (No. 1592, not in Register), 2-isopropyl-N,2,3-trimethylbutyramide [FL-no: 16.053], and piperidine [FL-no: 14.010]. Unscheduled DNA synthesis was not increased when WI-38 human cells were incubated with 125 - 2000 microgram/ml of 2-isopropyl-N,2,3-trimethylbutyramide (Skinner, 1978). No single-strand DNA breaks were reported when 0.03 - 1000 mM (2 - 59068 microgram/ml) of acetamide or 0.03 - 3 mM (2.6 to 255 microgram/ml) of piperidine were incubated with rat hepatocytes (Sina et al., 1983). Mixed results have been reported with tyramine and piperidine in the mouse lymphoma forward mutation assay: positive results were reported for both compounds when tested at up to 823 and 688 microgram/ml, respectively, in L5178Y mouse lymphoma cells with and without metabolic activation, but only at cytotoxic doses (Wangenheim & Bolcsfoldi, 1988). No mutagenic effects were reported when tyramine and 2-isopropyl-N,2,3-trimethylbutyramide were tested at concentrations of up to 3500 and 1000 microgram/ml, respectively, in L5178Y mouse lymphoma cells (Kirby et al., 1978; McGregor et al., 1988c). No mutagenic effects were observed when piperidine was tested at concentrations of up to 512 microgram/ml without metabolic activation in L5178Y mouse lymphoma cells; however, equivocal results were noted when metabolic activation was added (Garberg et al., 1988).

##### *In vivo*

In male and female C57B1/6, male CBA, male CD<sub>1</sub> and male BDF<sub>1</sub> mice, a single dose of acetamide (No. 1592, not in Register) of up to 5000 mg/kg bw did not induce micronuclei in the bone marrow or peripheral blood when administered by gavage or intraperitoneal injection (Mirkova, 1996; Morita et al., 1997). Micronuclei were found in the bone marrow of female C57B1/6 mice given 3.39 mmol/kg bw (approximately 200 mg/kg bw) of acetamide by gavage 30 and 6 h before termination; however, no dose-response relation was seen, as only a single dose was used (Chieli et al., 1987).

<sup>4</sup> The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

Piperine [FL-no: 14.003] did not induce micronuclei in the bone marrow of male Swiss mice given a single dose of 10 or 20 mg/kg bw by gavage (Karekar et al., 1996) or two intraperitoneal doses (at 0 and 24 h) for a total dose of up to 4 mg/kg bw (Muralidhara & Narasimhamurthy, 1990).

Male and female 1C3F<sub>1</sub> mice were given a single dose of 1000 mg/kg bw of 1,6-hexalactam [FL-no: 16.052] by gavage, and bone marrow was sampled from groups of 10 animals after 24, 30 and 48 h. Colchicine was administered to the mice 1 h before sacrifice. No chromosomal aberrations were seen (Adler & Ingwersen, 1989). The Comet assay was used to quantify DNA damage in cells from organs of male ddY mice given either acetamide (No. 1592, not in Register) or 1,6-hexalactam [FL-no: 16.052]. No DNA damage was reported in mice given a single dose of 2000 mg/kg bw 1,6-hexalactam by gavage; however, DNA damage was reported in the stomach, colon, lungs and bone marrow of male mice given a single intraperitoneal injection of acetamide at 2,000 mg/kg bw (Sasaki et al., 2000).

1,6-Hexalactam [FL-no: 16.052] did not induce replicative DNA synthesis in rat or mouse hepatocytes after treatment *in vivo* or *in vitro* at a dose of 350 or 700 mg/kg bw or 250 or 500 mg/kg bw, respectively (Uno et al., 1994; Miyagawa et al., 1995). In the mouse spot test, a single [route not stated but assumed to be intraperitoneal] injection of 1,6-hexalactam at a dose of up to 500 mg/kg bw significantly increased the frequency of spots over those in controls (Neuhäuser-Klaus & Lehmacher, 1989); however, statistically significant effects were observed in only one of three or four trials. It has been suggested that the colour spots observed were indicative of mitotic recombination and not mutation (Fahrig, 1989). Moreover, administration of 700 mg/kg bw in one trial did not significantly increase the frequency of spots over that in controls (Neuhäuser-Klaus & Lehmacher, 1989).

Female *Drosophila melanogaster* larvae fed up to 20 mmol/l (2263 microgram/ml) of 1,6-hexalactam [FL-no: 16.052] showed sex-linked recessive lethal mutations and somatic mutation-mitotic recombination, whereas male larvae fed up to 5 mmol/l (566 microgram/ml) did not have sex-linked recessive lethal mutations (Vogel, 1989).

Piperidine [FL-no: 14.010] and pyrrolidine [FL-no: 14.064] were tested for promoting activity in male Wistar rats given a single dose of 100 mg/kg bw of the test substance by gavage in dimethyl sulphoxide or 1 % Tylose. The number of mitoses in the adrenal cortex was examined 36 h after dosing. Only administration of pyrrolidine in dimethyl sulphoxide caused a statistically significant increase (approximately two-fold) in the number of mitoses over that in controls (Danz & Urban, 1979).

Piperine [FL-no: 14.003] and piperidine [FL-no: 14.010] did not cause mutations in male germ cells, as assessed by sperm shape abnormality and tests for dominant lethal mutations in mice and hamsters. Mice given piperine at doses of up to 75 mg/kg bw/day by gavage or up to 4 mg/kg bw per day by intraperitoneal injection for 5 days showed no sperm shape abnormalities or dominant lethal mutations (Muralidhara & Narasimhamurthy, 1990; Karekar et al., 1996; Daware et al., 2000). In another study, an oral dose of 400 mg/kg bw/day of piperidine for 40-100 days did not induce sperm shape abnormalities in mice or hamsters (Bempong & Scully, 1983).

#### *Conclusion on genotoxicity*

Negative results were reported in bacterial assays for reverse mutation with 15 aliphatic and aromatic amine and amide derivatives: ethylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, pentylamine, acetamide, 2-isopropyl-N,2,3-trimethylbutyramide, N-isobutyl (E,E)-2,4-decadienamide, piperine, piperidine, pyrrolidine, trimethylamine, triethylamine and piperazine.

Two substances, tyramine and piperidine, gave both positive and negative results in the mouse lymphoma assay, particularly at cytotoxic concentrations, while nitrosated tyramine gave positive results in the SOS Chromotest with *E. coli*.

Piperine and piperidine consistently gave negative results in a variety of studies *in vivo*, whereas acetamide, 1,6-hexalactam and pyrrolidine gave mainly negative results with some positive findings.

For a summary of *in vitro* / *in vivo* genotoxicity data considered by the JECFA, see Table 2.1.

### 3.2. EFSA Considerations

The only valid positive *in vivo* genotoxicity studies cited by the JECFA are related to acetamide, which the JECFA considered inappropriate to be used as a flavouring substance due to its reported carcinogenicity in both rats and mice, and consequently it was not evaluated using the Procedure.

As butyramide [FL-no: 16.049] is structurally related to acetamide the Panel concluded not to evaluate butyramide through the Procedure.

N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] (Nonivamide, pelargonyl vanillylamide (PAVA)) is structurally related to capsaicin. Capsaicin has been evaluated by SCF in 2002 (SCF, 2002h) and concluded to have shown genotoxic effects *in vitro* and *in vivo* and accordingly deleted from the Register. However, N-nonanoyl 4-hydroxy-3-methoxybenzylamide has more recently been evaluated by the UK Committee on Toxicity of Chemicals in Food in 2004 (COT, 2004) and concluded not to be an *in vivo* mutagen. The Panel agrees with this conclusion made by COT in 2004, based on the negative results of a bone marrow cytogenetic assay (COT, 2002) and an *in vivo* liver unscheduled DNA synthesis assay (Clay, 2003). Accordingly N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] can be evaluated through the Procedure along the B-side, which is also done by the JECFA.

For 1,6-hexalactam [FL-no: 16.052] the Panel noted an increased frequency of spots in only one of three or four trials in the mouse spot tests. In addition, sex-linked recessive lethal mutations and somatic mutations were reported in female *Drosophila* larvae fed 1,6-hexalactam. However, 1,6-hexalactam did not show carcinogenic effects in male and female mice and rats following daily administration for two years of up to 2250 mg/kg bw (mice) or up to 350 mg/kg bw (rats).

Otherwise, the Panel agreed with the JECFA that the available studies on genotoxicity did not preclude the evaluation of the aliphatic and aromatic amines and amides by using the Procedure.

For N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] additional genotoxicity data have been submitted by EFFA (Bowles, 2003). The substance was tested in a bacterial reverse mutation test using *S. typhimurium* strains TA98, TA100, TA1535, 1537 and *E. Coli* strain WP2uvrA with and without metabolic activation (see Table 2.2). It was concluded to be negative regarding the induction of mutagenicity.

## 4. Application of the Procedure

### 4.1. Application of the Procedure to 34 Aliphatic and Aromatic Amines and Amides by JECFA (JECFA, 2006d)

After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated intake was originally based on anticipated poundage data (JECFA, 2009c). New annual production volumes were submitted to the JECFA by the Flavour Industry for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052]. The JECFA concluded that there was “no safety concern” for these substances.

No new monograph was prepared, so all text about anticipated poundage in Section 4.1 below should not be taken into account.



### Step 1.

In applying the Procedure for the safety evaluation to these flavouring substances, the Committee assigned 15 substances [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.009, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026 and 16.092] to structural class I, nine flavouring substances [FL-no: 11.006, 11.007, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, and 16.049] to structural class II and the remaining ten flavouring substances [FL-no: 11.014, 11.017, 14.003, 16.006, 16.013, 16.052, 16.053, 16.091, 16.093 and 16.094] to structural class III.

### Step 2.

Twenty-four flavouring substances in this group, namely all those in structural classes I and II [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.049 and 16.092] are predicted to be metabolised to innocuous products. The evaluation of these substances therefore proceeded via the A-side of the Procedure.

For the ten flavouring substances in structural class III, namely the medium chain saturated and unsaturated aliphatic and alicyclic amides [FL-no: 11.017, 14.003, 16.006, 16.013, 16.052, 16.053, 16.091, 16.093 and 16.094] and N,N-dimethylphenethylamine [FL-no: 11.014], limited metabolic data were available, and evaluation of these substances therefore proceeded via the B-side of the Procedure.

### Step A3.

The estimated daily *per capita* exposures to all 15 flavouring substances in structural class I are below the threshold of concern (1800 microgram/person/day for class I). Three of these 15 substances [FL-no: 11.001, 11.003 and 11.009] are reported to be currently used as flavouring substances, and, according to the Procedure, the current use and exposure levels of these three substances raise no safety concern. The other 12 substances [FL-no: 11.002, 11.004, 11.005, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026 and 16.092] are proposed for use as flavouring substances. Although, according to the Procedure, the use of these 12 substances raises no safety concern at the exposure estimated from anticipated volumes of production, less uncertain estimates are needed. The estimated daily per capita exposure to all nine flavouring substances in structural class II is below the threshold of concern (540 microgram/day). Three of these nine substances [FL-no: 11.006, 14.010 and 14.064] are reported to be used as flavouring substances, and, according to the Procedure, their use raises no safety concern at current estimated level of exposure. The other six substances [FL-no: 11.007, 14.080, 14.133, 14.141, 14.167 and 16.049] are proposed for use as flavouring substances. Although, according to the Procedure, use of these six substances raises no safety concern at the exposure levels estimated from anticipated volumes of production, less uncertain exposure estimates are needed.

### Step B3.

The estimated *per capita* exposures to eight of the flavouring substances in structural class III [FL-no: 11.014, 11.017, 14.003, 16.006, 16.052, 16.091, 16.093 and 16.094] are below the threshold of concern (90 microgram/person/day). One of these substances [FL-no: 14.003] is reported to be used as a flavouring substance in Europe and the USA, one [FL-no: 16.006] is reported to be used in Europe and to be proposed for use in the USA, and six [FL-no: 11.014, 11.017, 16.052, 16.091, 16.093 and 16.094] are proposed for use in both regions. For those eight substances proposed for use in flavours in one or more region [FL-no: 11.014, 11.017, 14.003, 16.006, 16.052, 16.091, 16.093 and 16.094], less uncertain exposure estimates are needed. In accordance with the Procedure, evaluation of these eight flavouring substances proceeded to Step B4.



The *per capita* exposures in the USA of the two remaining flavouring substances in structural class III, 2-isopropyl-N-2,3-trimethylbutyramide ([FL-no: 16.053]; exposure, 1054 microgram/day) and N-ethyl-2-isopropyl-5-methylcyclohexane carboxamide ([FL-no: 16.013]; exposure, 127 microgram/day), exceed the threshold of concern for their structural class (90 microgram/person/day). In accordance with the Procedure, data must be available on these substances or closely related substances for a safety evaluation. For [FL-no: 16.053], which is proposed for use as a flavouring substance, a less uncertain exposure estimate is needed.

#### Step B4.

The No Observed Effect Level (NOEL) of 750 mg/kg bw/day for 1,6-hexalactam [FL-no: 16.052] in a 90-day feeding study in rats (NTP, 1982a) is at least  $2.5 \times 10^{10}$  times higher than the estimated exposure from its proposed use as a flavouring substance in Europe (0.00002 microgram/kg bw/day) and in the USA (0.00003 microgram/kg bw/day).

The NOEL of 572 mg/kg bw/day for the structurally related substance, N-isobutyl-2,6,8-decatrienamide [FL-no: 16.121] (Moore, 2002), is applicable to N-ethyl (2E,6Z)-nonadienamide [FL-no: 16.094], N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] and deca-(2E,4E)-dienoic acid isobutylamide [FL-no: 16.091], as they follow similar pathways of metabolism. This NOEL is 600000 times the estimated exposure to N-ethyl (2E,6Z)-nonadienamide [FL-no: 16.094] from its proposed use as a flavouring substance in the USA (1 microgram/kg bw/day) and is more than 800000 times the estimated exposure to N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] from its proposed use as flavouring substance in the USA (0.7 microgram/kg bw/day) and at least 600000 times the estimated exposure to deca-(2E,4E)-dienoic acid isobutylamide [FL-no: 16.091] from its proposed use as flavouring substance in Europe and in the USA (both 1 microgram/kg bw/day).

The NOEL of 8.4 mg/kg bw/day for N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] (Posternak et al., 1969) is more than 70000 times the estimated exposure from its proposed use as a flavouring substance in Europe (0.1 microgram/kg bw/day) and  $8.4 \times 10^6$  times that in the USA (0.001 microgram/kg bw/day).

The NOEL of 20 mg/kg bw/day for piperine [FL-no: 14.003] (Bhat & Chandrasekhara, 1986b) is 50000 times the estimated exposure to piperine from its reported use as a flavouring substance in Europe (0.4 microgram/kg bw/day) and  $2 \times 10^7$  times that in the USA (0.001 microgram/kg bw/day).

The NOEL of 115 mg/kg bw/day for the structurally related substance sec-butylamine [FL-no: 11.005] (Gage, 1970) is applicable to N-isopentylidene isopentylamine [FL-no: 11.017] and is at least  $5.75 \times 10^8$  times the estimated intake to N-isopentylidene isopentylamine from its proposed use as flavouring substance in Europe (0.0001 microgram/kg bw/day) and in the USA (0.0002 microgram/kg bw/day).

The NOEL of 247 ppm in a study in rats treated by inhalation (equivalent to an oral dose of 157 mg/kg bw/day) for the structurally related substance triethylamine [FL-no: 11.023] is applicable to N,N-dimethylphenethylamine [FL-no: 11.014] and is at least  $1 \times 10^8$  times the estimated exposure to N,N-dimethylphenethylamine from its proposed use as flavouring substance in Europe (0.001 microgram/kg bw/day) (Lynch et al., 1990; JECFA, 2006b).

#### *Consideration of flavour substances with high exposure, evaluated via the B-side of the Procedure*

In accordance with the Procedure, more data on toxicity were considered to evaluate the safety of 2-isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] and N-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 16.013], as the estimated exposure levels from proposed use [FL-no: 16.053] and reported use [FL-no: 16.013] as flavouring substances were determined to exceed the threshold of concern for structural class III (90 microgram per person per day).

The results of three studies in Sprague-Dawley (CD®) rats treated by gavage were available on 2-isopropyl-N-2,3-trimethylbutanamide [FL-no: 16.053]: a 14-day study in groups of six rats of each sex

at a dose of 0, 5, 25 or 50 mg/kg bw in corn oil twice daily (Nixon & Alden, 1978); a 14-week study in groups of 30 rats of each sex at a dose of 0, 10, 50 or 100 mg/kg bw in corn oil once daily (Pence, 1980a); and a 14-week study in groups of 30 rats of each sex at a dose of 0, 1, 2, 5, 10 or 50 mg/kg bw in corn oil once daily (Cheng, 1982). The studies showed treatment-related hepatic and renal toxicity at doses of 10 mg/kg bw and higher. The NOEL was 5 mg/kg bw/day, on the basis of histopathological lesions in the kidneys of male rats in the 14-week study (Cheng, 1982). A study of reproductive and teratogenic toxicity in rats at a dose of 0, 10, 50 or 100 mg/kg bw showed no reproductive effects or fetal abnormalities (Pence, 1980b). The NOEL of 5 mg/kg bw/day is 280 times the estimated daily exposure to 2-isopropyl-*N*-2,3-trimethylbutyramide [FL-no: 16.053] when used as a flavouring substance in the USA (18 microgram/kg bw/day).

Two studies were conducted on *N*-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 16.013] in rats treated by gavage: a 28-day study in groups of six Crj:CD(SD) rats of each sex at a dose of 0, 8, 40, 200 or 1000 mg/kg bw/day (Miyata, 1995) and a 22-week study in groups of 15 Sprague-Dawley (CFY) rats of each sex at a dose of 0, 100, 300 or 725 mg/kg bw/day. Mild toxicity in the liver and kidneys was observed at doses of 40 mg/kg bw and above. Two further studies were conducted in beagle dogs given gelatine capsules: a 28-day study in groups of one male and one female given a dose of 0, 600, 1000 or 1500 mg/kg bw/day and a 52-week study in groups of three animals of each sex given a dose of 0, 100, 300 or 1000 mg/kg bw/day (James, 1974). These studies showed mild toxic effects in the liver at all doses. The NOEL of 8 mg/kg bw/day in these studies is 1000000 times the estimated daily exposure to *N*-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide when used as a flavouring substance in Europe (0.008 microgram/kg bw/day) and 4000 times that in the USA (2 microgram/kg bw/day).

The additional toxicity data indicate that 2-isopropyl-*N*-2,3-trimethylbutyramide [FL-no: 16.053] and *N*-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 16.013] would not be expected to raise safety concerns at their estimated levels of exposure when used as flavouring substances. For one of these substances [FL-no: 16.053], however, less uncertain exposure estimates are needed, as the existing estimate was based on anticipated poundage.

In conclusion, the JECFA evaluated all 34 substances as to be of no safety concern at the estimated levels of intake as flavouring substances based on the MSDI approach.

The evaluations of the 34 aliphatic and aromatic amines and amides are summarised in Table 3.1: Summary of Safety Evaluation of 34 Aliphatic and Aromatic Amines and Amides (JECFA, 2006d).

## 4.2. EFSA Considerations

After the publication of FGE.86 Industry has submitted additional data (toxicity data and mutagenicity data) on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094]. However, for the present evaluation the Panel consider the substance [FL-no: 16.095] not to be sufficiently structurally related to candidate substances [FL-no: 16.091, 16.093 and 16.094] owing to the configuration of the amide bond and different characteristics of possible hydrolysis products (e.g. cyclopropyl amine and unsaturated carboxylic acid for [FL-no: 16.093] vs. cyclopropyl carboxylic acid and unsaturated amine for [FL-no: 16.095]; no cyclopropyl group in [FL-no: 16.091 and 16.094]. Due to these structural differences, routes of metabolism will also be different and also differences in toxicity must be anticipated.

The Panel agrees with the application of the Procedure as performed by the JECFA for 25 of the 34 substances in the group. Furthermore, for two more substances [FL-no: 11.006 and 16.053] the EU volumen has been provided since the publication of FGE.86. Based on the submitted EU production volumes, the Panel could also agree with the application of the Procedure as performed by the JECFA for these two substances. Further details can be found in FGE.96 (EFSA, 2010aj).

N-isopentylidene isopentylamine [FL-no: 11.017] is anticipated to be completely hydrolysed to isopentylamine and isopentylaldehyde, which are further metabolised to innocuous products. Accordingly [FL-no: 11.017] can be anticipated to be metabolised to innocuous products and evaluated along the A-side of the Procedure. The JECFA evaluated [FL-no: 11.017] along the B-side. As the estimated European *per capita* intake of 0.0073 microgram is below the threshold of concern for structural class III substances of 90 microgram/person/day, the Panel concluded (as did the JECFA) that there was no safety concern of the estimated level of intake of [FL-no: 11.017] based on the MSDI approach.

For butyramide [FL-no: 16.049] the Panel, contrary to the JECFA, concluded that this substance cannot be evaluated through the Procedure due to structural relationship to acetamide for which the Panel has concern with respect to carcinogenicity and a genotoxic mechanism which cannot be discounted.

In contrast to butyramide [FL-no: 16.049] the other amides in the present FGE are amides of alkylamines.

The JECFA derives a No Observed Adverse Effect Level (NOAEL) of 572 mg/kg bw/day for N-isobutyl-2,6,8-decatrienamide [FL-no: 16.121] from a 28-day feeding study with groups of 10 rats given different amounts of an extract of unknown purity from gold root (*Halopsis longiper*) with an estimated concentration of 50 % of N-isobutyl-2,6,8-decatrienamide (Moore, 2002). This study is also considered in FGE.303, in which N-isobutyl-2,6,8-decatrienamide [FL-no: 16.121] is the candidate substance. The Panel did not agree with the JECFA that the study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure for the three substances [FL-no: 16.091, 16.093 and 16.094], and accordingly additional data are required.

The JECFA derives a NOAEL of 20 mg/kg bw/day for piperine [FL-no: 14.003] from a 56-day feeding study in groups of six rats given different doses of black pepper or oleoresin corresponding to up to approximately 20 mg/kg bw/day or 100 mg piperine/kg feed corresponding to up to approximately 10 mg/kg bw/day. No histopathology was performed. The Panel did not agree with the JECFA that the study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure for piperine [FL-no: 14.003], and accordingly additional data are required.

The JECFA derives a NOAEL of 157 mg/kg bw/day from an inhalation study in groups of 100 rats exposed to 25 or 247 ppm triethylamine per day for up to 120 days, estimate to correspond to 25 to 157 mg/kg bw/day, respectively (Lynch et al., 1990). The Panel did not agree with the JECFA that the study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure for N,N-dimethylphenethylamine [FL-no: 11.014] (JECFA, 2006b) and accordingly additional data are required.

The Panel considered further the possible consequences of nitrosation after ingestion of the secondary and tertiary amine and secondary amide candidate substances according to the approach described in the Annex to the minutes of the 30<sup>th</sup> AFC Panel meeting, May 2008 (EFSA, 2008e). From these considerations, the Panel concluded that extremely large margins of exposure could be calculated ( $>10^9$ ) for nitrosated products possibly formed from amines used as flavouring substances in foods. Such large margins of exposure indicate that a risk of carcinogenicity resulting from such possible nitrosation products is virtually absent.

The Panel also noted that this conclusion is not applicable for foods preserved with nitrites, because for such foods the conditions for nitrosation, either in the foods themselves or after consumption in the stomach, may differ substantially from the worst-case conditions on which the calculations in the above mentioned Annex were based.

## 5. Conclusion

The Panel has considered 34 of 37 substances in the JECFA flavouring group of aliphatic and aromatic amines and amides. The Panel concluded that no corresponding FGE is available.

A further two substances were evaluated by the JECFA in this group, but these are not in the Register (1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, respectively). A third substance evaluated by the JECFA is an alpha,beta-unsaturated ketone [FL-no: 14.168] considered with respect to genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19, for which a final conclusion regarding its genotoxic properties could not be reached and additional data were requested. This consideration therefore only deals with 34 flavouring substances.

The Panel agreed with the application of the Procedure as performed by the JECFA for 27 of the 34 substances. The JECFA concluded on five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] at step B4, but the Panel did not agree that appropriate studies are available for deriving NOAELs and accordingly the Panel in FGE.86 concluded that additional toxicity data are required for these five substances.

The flavouring Industry has in response to the requested toxicity data in FGE.86 submitted additional data for three of the five substances [FL-no: 16.091, 16.093 and 16.094]. The following information has been submitted:

Ames test and acute oral toxicity test have been submitted by Industry on [FL-no: 16.093]. The Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 16.094]. These studies do not fulfil the suggested minimum requirement to provide an adequate NOAEL for flavourings in the Procedure, which is considered to be a 90-day study. The minimum requirement has not been met by the new toxicity data submitted by Industry for the substances in FGE.86 therefore additional toxicity data is still requested.

Further has Industry submitted Ames test and a 28 day study on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094]. The Panel did not consider [FL-no: 16.095] sufficiently structurally related to be used as supporting substance for this FGE.

In addition to the five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] for which the Panel did not agree that appropriate studies are available for deriving NOAELs, butyramide [FL-no: 16.049] cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicity. For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel concluded that this substance can be metabolised to innocuous products and accordingly evaluated along the A-side of the Procedure (while the JECFA evaluated [FL-no: 11.017] along the B-side). Like the JECFA the Panel concluded that [FL-no: 11.017] is of no safety concern at estimated level of intake, based on the MSDI approach. So, the Panel did not agree with the application of the Procedure as performed by the JECFA for 7 of the 34 substances.

For 22 substances evaluated by the JECFA through the Procedure use levels have been provided by the Industry [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 16.094]. The mTAMDI figures calculated for the substances in structural class I are 340 microgram/person/day, except for [FL-no: 16.092], for which the mTAMDI is 15000 microgram/person/day, exceeding the threshold of 1800 microgram/person/day for structural class I. The mTAMDI figures for the structural class II substances range from 200 to 340 microgram/person/day, except for [FL-no: 14.141] for which the figure is 600 microgram/person/day, exceeding the threshold of 540 microgram/person/day for structural class II. For the substances [FL-no: 11.014, 16.052, 16.091, 16.093 and 16.094] in structural class III the figures range from 200 to 1900 microgram/person/day, exceeding the threshold of concern of 90 microgram/person/day for structural class III. Thus, for seven substances [FL-no: 11.014, 14.141, 16.052, 16.091, 16.092, 16.093 and 16.094] the intakes, estimated on the basis of the

mTAMDI approach, exceed the threshold for their structural classes. Therefore more reliable exposure data are required. On the basis of such additional data, these flavouring substances should be considered using the Procedure. Subsequently, additional data might become necessary.

For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDI in order to identify those flavouring substances that need more refined exposure assessment and to finalise the evaluation.

In order to determine whether the conclusion for the 34 JECFA evaluated substances can be applied to the materials of commerce, it is necessary to consider the available specifications. Specifications including complete purity criteria and identity are available for 33 of the 34 JECFA evaluated substances. For one substance [FL-no: 16.013] information on the stereoisomeric composition is lacking.

Thus, for one substance [FL-no: 16.013] the Panel has reservation (information on stereoisomeric composition is requested).

For seven of the 34 evaluated substances the Panel did not agree with the JECFA application of the Procedure and additional toxicity data are required for five of the seven substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094]. One substance cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicity [FL-no: 16.049] and one substance [FL-no: 11.017] is evaluated along the A-side, while the JECFA evaluated it along the B-side.











Overall, for 27 of the 34 JECFA evaluated aliphatic and aromatic amines and amides [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 16.052, 16.053 and 16.092] the Panel agreed with the JECFA conclusion “no safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach.













**TABLE 1: SPECIFICATION SUMMARY**

*Table 1: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005d)*

**Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d)**











| FL-no<br>JECFA-<br>no | EU Register name              | Structural formula  | FEMA no<br>CoE no<br>CAS no | Phys.form<br>Mol.formula<br>Mol.weight                | Solubility 1)<br>Solubility in ethanol<br>2) | Boiling point, °C<br>3)<br>Melting point, °C<br>ID test<br>Assay minimum | Refrac.<br>Index 4)<br>Spec.gravity<br>5) | EFSA comments  |
|-----------------------|-------------------------------|---|-----------------------------|---|--|--|---|--|
| 11.001<br>1587        | 3-Methylbutylamine            |    | 3219<br>512<br>107-85-7     | Liquid<br>C <sub>5</sub> H <sub>13</sub> N<br>87.16   | Soluble<br>Soluble                           | 95-97<br>NMR<br>98 %   | 1.405-1.411<br>0.747-0.753                |  |
| 11.002<br>1583        | Isobutylamine                 |    | 513<br>78-81-9              | Liquid<br>C <sub>4</sub> H <sub>11</sub> N<br>73.14   | Soluble<br>Soluble                           | 68<br>MS<br>95 %   | 1.391-1.397<br>0.731-0.737                |  |
| 11.003<br>1582        | Butylamine                    |    | 3130<br>524<br>109-73-9     | Liquid<br>C <sub>4</sub> H <sub>11</sub> N<br>73.14   | Soluble<br>Soluble                           | 78<br>NMR<br>99 %  | 1.398-1.404<br>0.732-0.740                |  |
| 11.004<br>1580        | Propylamine                   |    | 601<br>107-10-8             | Liquid<br>C <sub>3</sub> H <sub>9</sub> N<br>59.11    | Soluble<br>Soluble                           | 48<br>MS<br>95 %   | 1.384-1.390<br>0.714-0.720                |  |
| 11.005<br>1584        | sec-Butylamine                |    | 707<br>13952-84-6           | Liquid<br>C <sub>4</sub> H <sub>11</sub> N<br>73.14   | Soluble<br>Soluble                           | 63<br>MS<br>95 %   | 1.387-1.393<br>0.715-0.721                | Racemate.  |
| 11.006<br>1589        | Phenethylamine                |   | 3220<br>708<br>64-04-0      | Liquid<br>C <sub>8</sub> H <sub>11</sub> N<br>121.18  | Soluble<br>Soluble                           | 194-195<br>NMR<br>95 %   | 1.526-1.532<br>(25°)<br>0.961-0.967       |  |
| 11.007<br>1590        | 2-(4-Hydroxyphenyl)ethylamine |  | 709<br>51-67-2              | Solid<br>C <sub>8</sub> H <sub>11</sub> NO<br>137.18  | Soluble<br>Soluble                           | 165<br>MS<br>95 %  | n.a.<br>n.a.                              |  |
| 11.009<br>1610        | Trimethylamine                |  | 3241<br>10497<br>75-50-3    | Gas<br>C <sub>3</sub> H <sub>9</sub> N<br>59.11       | Soluble<br>Soluble                           | 3-4<br>-<br>NMR<br>98 %  | n.a.<br>0.667-0.675<br>(4°)               |  |
| 11.014<br>1613        | N,N-Dimethylphenethylamine    |  | 19342-01-9                  | Liquid<br>C <sub>10</sub> H <sub>15</sub> N<br>149.24 | Soluble<br>Soluble                           | 183<br>MS<br>95 %  | 1.500-1.506<br>0.898-0.904                | Register name to be changed to (R)-N,N-Dimethylphenethylamine. |
| 11.015<br>1579        | Ethylamine                    |  | 10477                       | Gas<br>C <sub>2</sub> H <sub>7</sub> N                | Soluble<br>Soluble                           | 17<br>-81  | n.a.<br>0.682-0.686                       |  |

**Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d)**





| FL-no<br>JECFA-<br>no | EU Register name                | Structural formula  | FEMA no<br>CoE no<br>CAS no | Phys.form<br>Mol.formula<br>Mol.weight                              | Solubility 1)<br>Solubility in ethanol<br>2) | Boiling point, °C<br>3)<br>Melting point, °C<br>ID test<br>Assay minimum | Refrac.<br>Index 4)<br>Spec.gravity<br>5) | EFSA comments  |
|-----------------------|---------------------------------|---|-----------------------------|---|--|--|---|--|
|                       |                                 |   | 75-04-7                     | 45.08   |  | MS<br>95 %   | (10°)                                     |  |
| 11.016<br>1588        | Hexylamine                      |    | 10478<br>111-26-2           | Liquid<br>C <sub>6</sub> H <sub>15</sub> N<br>101.19                | Soluble<br>Soluble                           | 130<br>MS<br>95 %  | 1.415-1.421<br>0.761-0.767                |  |
| 11.017<br>1606        | N-Isopentylidene isopentylamine |    | 3990<br>35448-31-8          | Liquid<br>C <sub>10</sub> H <sub>21</sub> N<br>155.29               | Insoluble<br>Soluble                         | 145-148<br>MS<br>98 %  | 1.422-1.428<br>0.768-0.774                |  |
| 11.018<br>1581        | Isopropylamine                  |    | 10480<br>75-31-0            | Liquid<br>C <sub>3</sub> H <sub>9</sub> N<br>59.11                  | Soluble<br>Soluble                           | 34<br>MS<br>95 %   | 1.367-1.373<br>0.687-0.693                |  |
| 11.020<br>1586        | 2-Methylbutylamine              |    | 10484<br>96-15-1            | Liquid<br>C <sub>5</sub> H <sub>13</sub> N<br>87.16                 | Soluble<br>Soluble                           | 96<br>MS<br>95 %   | 1.417-1.423<br>0.777-0.779                | Racemate.  |
| 11.021<br>1585        | Pentylamine                     |    | 11734<br>110-58-7           | Liquid<br>C <sub>5</sub> H <sub>13</sub> N<br>87.16                 | Soluble<br>Soluble                           | 103<br>MS<br>95 %  | 1.418-1.424<br>0.750-0.759                |  |
| 11.023<br>1611        | Triethylamine                   |    | 10496<br>121-44-8           | Liquid<br>C <sub>6</sub> H <sub>15</sub> N<br>101.19                | Soluble<br>Soluble                           | 88<br>MS<br>95 %   | 1.395-1.401<br>0.724-0.730                |  |
| 11.025<br>1614        | Trimethylamine oxide            |   | 10494<br>1184-78-7          | Solid<br>C <sub>3</sub> H <sub>9</sub> NO<br>75.11                  | Soluble<br>Soluble                           | 213<br>MS<br>95 %  | n.a.<br>n.a.                              |  |
| 11.026<br>1612        | Tripropylamine                  |  | 10495<br>102-69-2           | Liquid<br>C <sub>9</sub> H <sub>21</sub> N<br>143.27                | Soluble<br>Soluble                           | 156<br>MS<br>95 %  | 1.411-1.417<br>0.754-0.760                |  |
| 14.003<br>1600        | Piperine                        |  | 2909<br>492<br>94-62-2      | Solid<br>C <sub>17</sub> H <sub>19</sub> O <sub>3</sub> N<br>285.34 | Very slightly soluble<br>Soluble             | 128-130<br>NMR<br>97 %   | n.a.<br>n.a.                              | CASrn in the Register refers to the (E,E)-isomer. Register name to be changed to (E,E)-piperidine. |
| 14.010<br>1607        | Piperidine                      |  | 2908<br>675<br>110-89-4     | Liquid<br>C <sub>5</sub> H <sub>11</sub> N<br>85.15                 | soluble<br>Soluble                           | 106<br>IR<br>98 %  | 1.450-1.454<br>0.858-0.862                |  |



**Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d)**

| FL-no<br>JECFA-<br>no | EU Register name                                    | Structural formula  | FEMA no<br>CoE no<br>CAS no | Phys.form<br>Mol.formula<br>Mol.weight                              | Solubility 1)<br>Solubility in ethanol<br>2) | Boiling point, °C<br>3)<br>Melting point, °C<br>ID test<br>Assay minimum | Refrac.<br>Index 4)<br>Spec.gravity<br>5) | EFSA comments   |
|-----------------------|---|---|-----------------------------|---|--|--|---|---|
| 14.064<br>1609        | Pyrrolidine   |    | 3523<br>10491<br>123-75-1   | Liquid<br>C <sub>4</sub> H <sub>9</sub> N<br>71.12                  | Soluble<br>Freely soluble                    | 87-89<br><br>IR NMR<br>95 %  | 1.440-1.446<br>0.847-0.853                |   |
| 14.080<br>1604        | 2-Acetyl-1-pyrroline                                |    | 99583-29-6                  | Solid<br>C <sub>6</sub> H <sub>9</sub> NO<br>111.14                 | Soluble<br>Soluble                           | 19<br>MS<br>95 %   | n.a.<br>n.a.                              |   |
| 14.133<br>1608        | 2-Methylpiperidine                                  |    | 109-05-7                    | Liquid<br>C <sub>6</sub> H <sub>13</sub> N<br>99.18                 | Soluble<br>Soluble                           | 118<br><br>MS<br>95 %  | 1.442-1.448<br>0.838-0.844                | Racemate  |
| 14.141<br>1615        | Piperazine  |    | 110-85-0                    | Solid<br>C <sub>4</sub> H <sub>10</sub> N <sub>2</sub><br>86.14     | Soluble<br>soluble                           | 109<br>MS<br>95 %  | n.a.<br>n.a.                              |   |
| 14.167<br>1603        | 1-Pyrroline   |    | 5724-81-2                   | Liquid<br>C <sub>4</sub> H <sub>7</sub> N<br>69.10                  | Soluble<br>Soluble                           | 87-89<br><br>NMR<br>99 %   | 1.440-1.446<br>0.849-0.855                |   |
| 16.006<br>1599        | N-Nonanoyl 4-hydroxy-3-methoxybenzylamide           |    | 2787<br>590<br>2444-46-4    | Solid<br>C <sub>17</sub> H <sub>27</sub> O <sub>3</sub> N<br>293.41 | Slightly soluble<br>Soluble                  | 124-128<br>NMR<br>96 %   | n.a.<br>n.a.                              |   |
| 16.013<br>1601        | N-Ethyl-2-isopropyl-5-methylcyclohexane carboxamide |   | 3455<br>2298<br>39711-79-0  | Solid<br>C <sub>13</sub> H <sub>25</sub> ON<br>211.35               | Insoluble<br>Soluble                         | 91-93<br>NMR<br>98 %   | n.a.<br>n.a.                              | Mixture of diastereoisomers (EFA, 2010a). Range should be given. CASrn in Register does not specify stereoisomeric composition. |
| 16.049<br>1593        | Butyramide  |  | 541-35-5                    | Solid<br>C <sub>4</sub> H <sub>9</sub> NO<br>87.12                  | Soluble<br>Soluble                           | 115<br>NMR MS<br>95 %  | n.a.<br>n.a.                              |   |
| 16.052<br>1594        | 1,6-Hexalactam                                      |  | 105-60-2                    | Solid<br>C <sub>6</sub> H <sub>11</sub> NO<br>113.16                | Soluble<br>Soluble                           | 70<br>NMR MS<br>95 %   | n.a.<br>n.a.                              |   |
| 16.053<br>1595        | 2-Isopropyl-N,2,3-trimethylbutanamide               |  | 3804<br>10459<br>51115-67-4 | Solid<br>C <sub>10</sub> H <sub>21</sub> ON<br>171.28               | insoluble<br>Soluble                         | 56-64<br>NMR<br>99 %   | n.a.<br>n.a.                              |   |








**Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d)**

| FL-no<br>JECFA-<br>no | EU Register name                             | Structural formula  | FEMA no<br>CoE no<br>CAS no | Phys.form<br>Mol.formula<br>Mol.weight  | Solubility 1)<br>Solubility in ethanol<br>2) | Boiling point, °C<br>3)<br>Melting point, °C<br>ID test<br>Assay minimum | Refrac.<br>Index 4)<br>Spec.gravity<br>5) | EFSA comments   |
|-----------------------|--|---|-----------------------------|---|--|--|---|---|
| 16.091<br>1598        | Deca-(2E,4E)-dienoic acid isobutyl-<br>amide |  | 18836-52-7                  | Solid<br>C <sub>14</sub> H <sub>23</sub> NO<br>223.36                             | Insoluble<br>Soluble                         | 82-90<br>IR NMR MS<br>95 %   | n.a.<br>n.a.                              |   |
| 16.092<br>1602        | N,N-Dimethyl menthyl succinamide             |  | 544714-08-<br>1             | Liquid<br>C <sub>16</sub> H <sub>30</sub> O <sub>2</sub> N <sub>2</sub><br>282.43 | Slightly soluble<br>Soluble                  | 380<br>IR NMR<br>95 %  | 1.522-1.530<br>0.965-0.975                | Register name to be changed to (1R,2S,5R) N,N-Dimethyl menthyl succinamide. |
| 16.093<br>1597        | N-Cyclopropyl (2E,6Z)-<br>nonadienamide      |  | 608514-55-<br>2             | Solid<br>C <sub>12</sub> H <sub>19</sub> NO<br>193.29                             | Sparingly soluble<br>Soluble                 | 33-37<br>IR NMR<br>95 %  | n.a.<br>n.a.                              |   |
| 16.094<br>1596        | N-Ethyl (2E,6Z)-nonadienamide                |  | 608514-56-<br>3             | Liquid<br>C <sub>11</sub> H <sub>19</sub> NO<br>181.28                            | Sparingly soluble<br>Soluble                 | 120 ( 0.8 hPa)<br>IR NMR MS<br>96 %                                      | 1.484-1.493<br>0.910-0.920                |   |





- 1) Solubility in water, if not otherwise stated.
- 2) Solubility in 95 % ethanol, if not otherwise stated.
- 3) At 1013.25 hPa, if not otherwise stated.
- 4) At 20°C, if not otherwise stated.
- 5) At 25°C, if not otherwise stated.

### TABLE 2: GENOTOXICITY DATA






*Table 2.1: Genotoxicity Data (in vitro / in vivo) for 34 Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)*

| FL-no<br>JECFA-<br>no | EU Register name<br>JECFA name | Structural formula  | End-point                | Test system   | Concentration  | Results                 | Reference                       |
|-----------------------|--------------------------------|---|--------------------------|---|--|-------------------------|---------------------------------|
| <i>In vitro</i>       |                                |   |                          |   |  |                         |                                 |
| 11.015<br>1579        | Ethylamine                     |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 100 to 10,000 µg/plate   | Negative <sup>1</sup>   | (Mortelmans et al., 1986)       |
| 11.018<br>1581        | Isopropylamine                 |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 10 to 10,000 µg/plate  | Negative <sup>1</sup>   | (Zeiger et al., 1987)           |
| 11.003<br>1582        | Butylamine                     |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 3.3 to 3,333 µg/plate  | Negative <sup>1</sup>   | (Zeiger et al., 1987)           |
|                       |                                |   | Reverse Mutation         | <i>S. typhimurium</i> TA100   | 3 µmol/plate (219 µg/plate) <sup>2</sup>   | Negative <sup>1</sup>   | (Florin et al., 1980)           |
| 11.002<br>1583        | Isobutylamine                  |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 33 to 10,000 µg/plate  | Negative <sup>1</sup>   | (Mortelmans et al., 1986)       |
| 11.005<br>1584        | sec-Butylamine                 |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 10 to 3,333 µg/plate   | Negative <sup>1</sup>   | (Zeiger et al., 1987)           |
| 11.021<br>1585        | Pentylamine                    |    | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 33 to 3,333 µg/plate   | Negative <sup>1</sup>   | (Mortelmans et al., 1986)       |
| 11.007<br>1590        | 2-(4-Hydroxyphenyl)ethylamine  |  | Forward Mutation         | Mouse lymphoma L5178Y cells   | 500 to 3,500 µg/ml   | Negative                | (McGregor et al., 1988)         |
|                       |                                |   | Forward Mutation         | Mouse lymphoma L5178Y cells   | 0.08, 0.80, 2.0, 4.0 or 6.0 mM (11, 109, 274, 548 and 823 µg/ml) <sup>3,4</sup>  | Positive <sup>5,6</sup> | (Wangenheim & Bolcsfoldi, 1988) |
|                       |                                |   | Forward Mutation         | Mouse lymphoma L5178Y cells   | 0.40, 0.80, 1.60, 2.39 or 3.20 mM (55, 109, 220, 327 and 439 µg/ml) <sup>3,4</sup>   | Positive <sup>6,7</sup> | (Wangenheim & Bolcsfoldi, 1988) |
| 1592                  | Acetamide (not in Register)    |   | Reverse Mutation         | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 100 to 10,000 µg/plate   | Negative <sup>1</sup>   | (Haworth et al., 1983)          |
|                       |                                |   | DNA Repair               | <i>Escherichia coli</i> 343/591 <i>uvrB</i> <sup>+</sup> / <i>recA</i> <sup>+</sup> / <i>lac</i> <sup>+</sup> and <i>uvrB</i> <sup>-</sup> / <i>recA</i> <sup>-</sup> / <i>lac</i> <sup>+</sup> | Up to 1,080 mM (63,793 µg/ml) <sup>8</sup>   | Negative <sup>1</sup>   | (Hellmér & Bolcsfoldi, 1992a)   |
|                       |                                |   | Single Strand DNA Breaks | Rat hepatocytes   | 0.03, 0.3, 3, 10, 30, 100, 300, or 1,000 mM (2, 18, 177, 591, 1,772, 5,316, 15,948, 47,844, 143,532, 430,596, 1,291,788, 3,875,364, 11,626,092, 34,878,276, 104,634,828, 313,904,484, 941,713,452, 2,825,140,356, 847,542,106, 2,542,626,396, 7,627,879,188, 228,836,595, 686,509,784, 2,059,529,352, 617,858,806, 1,853,576,416, 556,072,928, 1,668,218,784, 493,268,832, 147,980,640, 443,941,920, 133,182,576, 400,547,776, 120,164,336, 360,493,008, 108,147,904, 324,443,712, 97,333,104, 291,999,312, 87,599,792, 262,799,376, 78,839,808, 236,519,424, 70,955,824, 212,867,472, 63,860,224, 191,580,672, 57,474,192, 172,422,576, 51,318,752, 153,956,256, 45,597,696, 136,793,088, 40,797,920, 122,393,760, 36,718,128, 109,154,384, 32,746,304, 98,238,912, 29,471,672, 88,415,008, 26,526,512, 79,579,536, 23,860,656, 71,581,968, 21,546,592, 64,639,776, 19,391,920, 58,175,760, 17,537,024, 52,611,072, 15,783,328, 47,349,984, 14,191,984, 42,575,952, 12,747,984, 38,243,952, 11,415,984, 34,247,952, 10,171,984, 30,515,952, 8,967,984, 27,047,952, 8,063,984, 24,191,952, 7,259,984, 21,547,952, 1,951,984, 58,643,952, 1,663,984, 49,787,952, 1,375,984, 40,931,952, 1,090,984, 32,075,952, 805,984, 23,219,952, 617,984, 17,367,952, 429,984, 12,515,952, 341,984, 9,663,952, 253,984, 7,811,952, 195,984, 5,059,952, 127,984, 3,207,952, 80, |                         |                                 |





**Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA**

| FL-no<br>JECFA-<br>no | EU Register name<br>JECFA name          | Structural formula  | End-point                                  | Test system   | Concentration   | Results                 | Reference                          |
|-----------------------|---|---|--|---|---|-------------------------|------------------------------------|
|                       |   |   |  |   | 5,907, 17,720, or 59,068<br>µg/ml) <sup>8</sup>   |                         |                                    |
| 16.053<br>1595        | 2-Isopropyl- N,2,3-trimethylbutanamide  |  | Reverse Mutation                           | <i>S. typhimurium</i> TA98,<br>TA100, TA1535,<br>TA1537, TA1538 | 200, 1,000, 5,000,<br>10,000 or 20,000<br>µg/plate  | Negative <sup>1</sup>   | Haworth <i>et al.</i> (1978)       |
|                       |   |   | Forward Mutation                           | Mouse lymphoma<br>L5178Y cells                                  | 0.01 to 1,000 µg/ml   | Negative <sup>1</sup>   | Kirby <i>et al.</i> (1978)         |
|                       |   |   | Unscheduled DNA Synthesis                  | WI-38 cells (human)   | 125 to 2,000 µg/ml <sup>9</sup>   | Negative <sup>1</sup>   | Skinner (1978)                     |
| 16.091<br>1598        | Deca-(2E,4E)-dienoic acid isobutylamide |  | Reverse Mutation                           | <i>S. typhimurium</i> TA98,<br>TA100, TA102,<br>TA1535, TA1537  | 5 to 1,500 µg/plate <sup>10</sup>   | Negative <sup>5</sup>   | King (2003)                        |
|                       |   |   | Reverse Mutation                           | <i>S. typhimurium</i> TA98,<br>TA100, TA102,<br>TA1535, TA1537  | 5 to 5,000 µg/plate <sup>11</sup>   | Negative <sup>7</sup>   | King (2003)                        |
| 14.003<br>1600        | Piperine                                |  | Reverse Mutation                           | <i>S. typhimurium</i> TA97a,<br>TA98, TA100, TA102              | 0.01, 0.5 or 10<br>µmol/plate (3, 143 and<br>2,853 µg/plate) <sup>12</sup>                  | Negative <sup>1</sup>   | (Karekar <i>et al.</i> , 1996)     |
|                       |   |   | Reverse Mutation (pre-<br>incubation)      | <i>S. typhimurium</i> TA97a,<br>TA98, TA100, TA102              | 0.005, 0.05, 0.5 or 5<br>µmol/plate (1, 14, 143<br>and 1,427 µg/plate) <sup>12,13</sup>     | Negative <sup>1</sup>   | (Karekar <i>et al.</i> , 1996)     |
|                       |   |   | Reverse Mutation                           | <i>S. typhimurium</i> TA98,<br>TA100, TA1535,<br>TA1537, TA1538 | 1,000 µg  | Negative <sup>1</sup>   | (Andrews <i>et al.</i> , 1980)     |
| 14.010<br>1607        | Piperidine                              |  | Reverse Mutation                           | <i>S. typhimurium</i> TA98,<br>TA100, TA1535,<br>TA1537         | 3 µmol/plate (255<br>µg/plate) <sup>14</sup>  | Negative <sup>1</sup>   | (Florin <i>et al.</i> , 1980)      |
|                       |   |   | Reverse Mutation                           | <i>S. typhimurium</i> TA1530,<br>TA1531, TA1532,<br>TA1964      | 1 to 5 mg/plate (1,000 to<br>5,000 µg/plate) <sup>14</sup>                                  | Negative                | (Green & Savage, 1978)             |
|                       |   |   | Reverse Mutation<br>(microsomal assay)     | <i>S. typhimurium</i> TA1530,<br>TA1531, TA1532,<br>TA1964      | 0.15 M (12,772<br>µg/ml) <sup>14,15</sup>   | Negative                | (Green & Savage, 1978)             |
|                       |   |   | Reverse Mutation (host-<br>mediated, mice) | <i>S. typhimurium</i> TA1950,<br>TA1951, TA1952,<br>TA1964      | 800 mg/kg bw <sup>16</sup>  | Negative                | (Green & Savage, 1978)             |
|                       |   |   | Forward Mutation                           | Mouse lymphoma<br>L5178Y cells                                  | 3.03, 4.04, 5.05, 6.06 or<br>7.07 mM (258, 344,<br>430, 516 and 602<br>µg/ml) <sup>14</sup> | Positive <sup>5,6</sup> | (Wangenheim &<br>Bolcsfoldi, 1988) |
|                       |   |   | Forward Mutation                           | Mouse lymphoma<br>L5178Y cells                                  | 4.04, 5.05, 6.06, 7.07 or<br>8.08 mM (344, 430,<br>516, 602 and 688<br>µg/ml) <sup>14</sup> | Negative <sup>7</sup>   | (Wangenheim &<br>Bolcsfoldi, 1988) |
|                       |   |   | Forward Mutation                           | Mouse lymphoma<br>L5178Y cells                                  | 2.0, 4.01, or 6.01 mM<br>(170, 341 and 512<br>µg/ml) <sup>14</sup>                          | Negative <sup>5</sup>   | (Garberg <i>et al.</i> , 1988)     |
|                       |   |   | Forward Mutation                           | Mouse lymphoma  | 2.0, 4.01, 6.01 or 8.02   | Equivocal               | (Garberg <i>et al.</i> , 1988)     |

**Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA**

| FL-no<br>JECFA-<br>no | EU Register name<br>JECFA name | Structural formula  | End-point                                      | Test system   | Concentration   | Results                | Reference                     |
|-----------------------|--------------------------------|---|--|---|---|------------------------|-------------------------------|
|                       |                                |   |  | L5178Y cells  | mM (170, 341, 512 and 683 µg/ml) <sup>14</sup>          | <sup>7,17</sup>        |                               |
|                       |                                |   | DNA Repair                                     | <i>Escherichia coli</i> 343/591 <i>uvrB</i> <sup>+</sup> / <i>recA</i> <sup>+</sup> / <i>lac</i> <sup>+</sup> and <i>uvrB</i> <sup>+</sup> / <i>recA</i> <sup>+</sup> / <i>lac</i> <sup>+</sup> | 33.7 mM (2,870 µg/ml) <sup>14,18</sup>                  | Negative <sup>5</sup>  | (Hellmér & Bolcsfoldi, 1992a) |
|                       |                                |   | DNA Repair                                     | <i>Escherichia coli</i> 343/591 <i>uvrB</i> <sup>+</sup> / <i>recA</i> <sup>+</sup> / <i>lac</i> <sup>+</sup> and <i>uvrB</i> <sup>+</sup> / <i>recA</i> <sup>+</sup> / <i>lac</i> <sup>+</sup> | 101 mM (8,600 µg/ml) <sup>14,18</sup>                   | Negative <sup>5</sup>  | (Hellmér & Bolcsfoldi, 1992a) |
|                       |                                |   | Single Strand DNA Breaks                       | Rat hepatocytes   | 0.03, 0.3 or 3 mM (2.6, 26 and 255 µg/ml) <sup>14</sup> | Negative               | (Sina et al., 1983)           |
| 14.064<br>1609        | Pyrrolidine                    |    | Reverse Mutation                               | <i>S. typhimurium</i> TA100   | Up to 3 µmol/plate (213 µg/plate) <sup>19</sup>         | Negative <sup>1</sup>  | (Florin et al., 1980)         |
|                       |                                |   | Reverse Mutation                               | <i>S. typhimurium</i> TA1530, TA1531, TA1532, TA1964  | 1 to 5 mg/plate (1,000 to 5,000 µg/plate) <sup>3</sup>  | Negative               | (Green & Savage, 1978)        |
|                       |                                |   | Reverse Mutation (microsomal assay)            | <i>S. typhimurium</i> TA1530, TA1531, TA1532, TA1964  | 0.5 M (35,561 µg/ml) <sup>19</sup>                      | Negative               | (Green & Savage, 1978)        |
|                       |                                |   | Reverse Mutation (host-mediated, mice)         | <i>S. typhimurium</i> TA1950, TA1951, TA1952, TA1964  | 800 mg/kg bw <sup>16</sup>                              | Negative               | (Green & Savage, 1978)        |
| 11.009<br>1610        | Trimethylamine                 |    | Reverse Mutation                               | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 10 to 1,000 µg/plate                                    | Negative <sup>1</sup>  | (Mortelmans et al., 1986)     |
| 11.023<br>1611        | Triethylamine                  |    | Reverse Mutation                               | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 10 to 10,000 µg/plate                                   | Negative <sup>1</sup>  | (Zeiger et al., 1987)         |
| 14.141<br>1615        | Piperazine                     |   | Reverse Mutation                               | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537   | 33 to 3,167 µg/plate                                    | Negative <sup>1</sup>  | (Haworth et al., 1983)        |
| <b>In vivo</b>        |                                |   |  |   |   |                        |                               |
| 1592                  | Acetamide (not in Register)    |   | DNA Damage (Comet assay)                       | Male ddy mice   | 2,000 mg/kg bw <sup>20</sup>                            | Positive <sup>21</sup> | (Sasaki et al., 2000)         |
|                       |                                |   | Micronuclei (bone marrow)                      | C57B1/6 mice  | 2,500 or 5,000 mg/kg bw <sup>22</sup>                   | Negative               | (Mirkova, 1996)               |
|                       |                                |   | Micronuclei (bone marrow)                      | Male CBA mice   | 5,000 mg/kg bw <sup>22</sup>                            | Negative               | (Mirkova, 1996)               |
|                       |                                |   | Micronuclei (bone marrow and peripheral blood) | Male CD1 mice   | 500 to 5,000 mg/kg bw <sup>23</sup>                     | Negative               | (Morita et al., 1997)         |
|                       |                                |   | Micronuclei (bone marrow and peripheral blood) | Male BDF1 mice  | 1,250 to 5,000 mg/kg bw <sup>23</sup>                   | Negative               | (Morita et al., 1997)         |
|                       |                                |   | Micronuclei (bone marrow)                      | Female C57B1/6 mice   | 3.39 mmol/kg bw (200 mg/kg bw) <sup>24,25</sup>         | Positive               | (Chieli et al., 1987)         |
| 16.052<br>1594        | 1,6-Hexalactam                 |  | DNA Damage (Comet assay)                       | Male ddy mice   | 2,000 mg/kg bw <sup>22</sup>                            | Negative               | (Sasaki et al., 2000)         |
|                       |                                |   | Replicative DNA Synthesis                      | Male F344 rats  | 350 or 700 mg/kg bw <sup>26</sup>                       | Negative               | (Uno et al., 1994)            |
|                       |                                |   | Replicative DNA Synthesis                      | Male B6C3F <sub>1</sub> mice  | 250 or 500 mg/kg bw <sup>22</sup>                       | Negative               | (Miyagawa et al., 1995)       |

**Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA**

| FL-no<br>JECFA-<br>no | EU Register name<br>JECFA name | Structural formula  | End-point                              | Test system                                  | Concentration   | Results                | Reference                             |
|-----------------------|--------------------------------|---|--|--|---|------------------------|---------------------------------------|
| 14.003<br>1600        | Piperine                       |    | Mammalian Spot                         | (C57B1xT) <sub>F1</sub> mouse embryos        | 400 or 500 mg/kg bw <sup>22</sup>   | Positive <sup>27</sup> | (Fahrig, 1989)                        |
|                       |                                |   | Mammalian Spot                         | (TxHT) <sub>F1</sub> mouse embryos           | 500 mg/kg bw <sup>28</sup>  | Positive <sup>29</sup> | (Neuhäuser-Klaus & Lehmacher, 1989)   |
|                       |                                |   | Mammalian Spot                         | (TxHT) <sub>F1</sub> mouse embryos           | 700 mg/kg bw <sup>28</sup>  | Negative               | (Neuhäuser-Klaus & Lehmacher, 1989)   |
|                       |                                |   | Sex-Linked Recessive Lethals           | Male <i>Drosophila melanogaster</i> larvae   | 5.0 mM <sup>30</sup> (566 µg/ml) <sup>31</sup>  | Negative               | (Vogel, 1989)                         |
|                       |                                |   | Sex-Linked Recessive Lethals           | Female <i>Drosophila melanogaster</i> larvae | 5.0 or 20.0 mM <sup>30</sup> (566 or 2,263 µg/ml) <sup>31</sup>                         | Positive               | (Vogel, 1989)                         |
|                       |                                |   | Somatic Mutation/Mitotic Recombination | Female <i>Drosophila melanogaster</i> larvae | 2.5, 5.0, 10.0 or 20.0 mM <sup>30</sup> (283, 566, 1,132 and 2,263 µg/ml) <sup>31</sup> | Positive               | (Vogel, 1989)                         |
|                       |                                |   | Chromosomal Aberrations (bone marrow)  | Male and female 1C3F <sub>1</sub> mice       | 1,000 mg/kg bw <sup>22</sup>  | Negative               | (Adler & Ingwersen, 1989)             |
|                       |                                |   | Micronuclei (bone marrow)              | Male Swiss mice                              | 10 or 20 mg/kg bw <sup>22</sup>   | Negative               | (Karekar et al., 1996)                |
|                       |                                |   | Micronuclei (bone marrow)              | Male Swiss mice                              | 1, 2 or 4 mg/kg bw <sup>32</sup>  | Negative               | (Muralidhara & Narasimhamurthy, 1990) |
|                       |                                |   | Sperm Morphology                       | Male Swiss mice                              | 10 or 50 mg/kg bw/day <sup>33</sup>   | Negative               | (Karekar et al., 1996)                |
| 14.010<br>1607        | Piperidine                     |  | Sperm Morphology                       | Male Swiss mice                              | 35, 50 or 75 mg/kg bw/day <sup>34</sup>   | Negative               | (Daware et al., 2000)                 |
|                       |                                |   | Sperm Morphology                       | Male Swiss mice                              | 1, 2 or 4 mg/kg bw/day <sup>35</sup>  | Negative               | (Muralidhara & Narasimhamurthy, 1990) |
|                       |                                |   | Dominant Lethal Mutations              | Male and Female Swiss mice                   | 10 or 50 mg/kg bw <sup>22</sup>   | Negative               | (Karekar et al., 1996)                |
|                       |                                |   | Dominant Lethal Mutations              | Male Swiss mice                              | 4 mg/kg bw/day <sup>35</sup>  | Negative               | (Muralidhara & Narasimhamurthy, 1990) |
| 14.064<br>1609        | Pyrrolidine                    |  | Mitosis in Adrenocortical Cells        | Male Wistar rats                             | 100 mg/kg bw in DMSO <sup>22</sup>  | Negative               | (Danz & Urban, 1979)                  |
|                       |                                |   | Mitosis in Adrenocortical Cells        | Male Wistar rats                             | 100 mg/kg bw in 1% Tylose <sup>32</sup>   | Negative               | (Danz & Urban, 1979)                  |
|                       |                                |   | Sperm Morphology                       | Male hybrid mice                             | 400 mg/kg bw/day <sup>36</sup>  | Negative               | (Bempong & Scully, 1983)              |
|                       |                                |   | Sperm Morphology                       | Male golden Syrian hamsters                  | 400 mg/kg bw/day <sup>36</sup>  | Negative               | (Bempong & Scully, 1983)              |
| 14.064<br>1609        | Pyrrolidine                    |  | Mitosis in Adrenocortical Cells        | Male Wistar rats                             | 100 mg/kg bw in 1% Tylose <sup>32</sup>   | Negative               | (Danz & Urban, 1979)                  |
|                       |                                |   | Mitosis in Adrenocortical Cells        | Male Wistar rats                             | 100 mg/kg bw in DMSO <sup>22</sup>  | Positive               | (Danz & Urban, 1979)                  |

<sup>1</sup> With and without S9.

<sup>2</sup> Calculated using the molecular weight of butylamine (73.14 g/mol).

<sup>3</sup> Calculated using the molecular weight of tyramine (137.18 g/mol).



<sup>4</sup> Actual compound used in this study was tyramine hydrochloride at concentrations of 0.101 to 7.59 mM (18 to 1,318 µg/ml) without metabolic activation, and 0.506 to 4.05 mM (88 to 703 µg/ml) with metabolic activation.

<sup>5</sup> Without metabolic activation.

- <sup>6</sup> Significant increases in mutation frequency were observed only at cytotoxic doses.
- <sup>7</sup> With metabolic activation.
- <sup>8</sup> Calculated using the molecular weight of acetamide (59.07 g/mol).
- <sup>9</sup> Cytotoxic at 2,000 µg/ml.
- <sup>10</sup> Toxic and precipitates at 1,500 µg/plate.
- <sup>11</sup> Toxic and precipitates at 5,000 µg/plate.
- <sup>12</sup> Calculated using the molecular weight of piperine (285.34 g/mol).
- <sup>13</sup> Toxic at 5 µmol/plate without metabolic activation.
- <sup>14</sup> Calculated using the molecular weight of piperidine (85.15 g/mol).
- <sup>15</sup> Highest non-cytotoxic concentration.
- <sup>16</sup> Intraperitoneal injection of *S. typhimurium* strain with intramuscular injection of test material.
- <sup>17</sup> Results observed did not meet the criteria for positive or negative classification.
- <sup>18</sup> Concentration at which a significant reduction in the number of colonies of each strain was observed; however, the highest concentration of piperidine tested was 1,010 mM.
- <sup>19</sup> Calculated using the molecular weight of pyrrolidine (71.12 g/mol).
- <sup>20</sup> Administered via a single intraperitoneal injection.
- <sup>21</sup> Increase in DNA damage was observed in the stomach, colon, lungs and bone marrow of mice.
- <sup>22</sup> Administered via a single gavage dose.
- <sup>23</sup> Single, double, or quadruple intraperitoneal injections, separated by 24 hours, were administered.
- <sup>24</sup> Administered by gavage at 30 and 6 hours prior to sacrifice.
- <sup>25</sup> Calculated using the molecular weight of acetamide (59.07 g/mol).
- <sup>26</sup> Administered via a single subcutaneous injection.
- <sup>27</sup> Frequency of spots of genetic relevance was significantly increased relative to controls only in 1 out of 3 trials, and only at the highest dose (500 mg/kg bw).
- <sup>28</sup> Administered at a single dose (route not specified).
- <sup>29</sup> Significant increase in spots of genetic relevance was observed only in 1 out of 4 groups receiving 500 mg/kg body weight.
- <sup>30</sup> Administered in the diet.
- <sup>31</sup> Calculated using the molecular weight of 1,6-hexalactam (113.16 g/mol).
- <sup>32</sup> Intraperitoneal injection in 2 installments at 0 and 24 hours.
- <sup>33</sup> Administered via gavage for 5 days.
- <sup>34</sup> Administered orally for 5 consecutive days.
- <sup>35</sup> Administered intraperitoneally for 5 days, followed by a 35-day maintenance period.
- <sup>36</sup> Piperidine was administered orally to mice for 100 days. However, on day 40 and every subsequent 5 days, 3 mice were killed for examination of sperm morphology.











**Table 2.2: Additional genotoxicity data submitted by the Industry**

| FL-no<br>JECFA-<br>no  | EU Register name<br>JECFA name                          | Structural formula  | End-point        | Test system  | Concentration       | Results               | Reference                            | Comments  |
|------------------------|---|---|------------------|--|---------------------|-----------------------|--------------------------------------|---|
| <b><i>In vitro</i></b> |   |   |                  |  |                     |                       |                                      |   |
| 16.093<br>1597         | N-Cyclopropyl (2E,6Z)-nonadienamide                     |  | Reverse Mutation | <i>S.typhimurium</i> TA98,<br>TA100, TA1535,<br>TA1537 | Up to 5000 µg/plate | Negative <sup>1</sup> | (Bowles, 2003)                       |   |
| 16.095<br>1779         | N-3,7-Dimethyl-2,6-octadienyl<br>cyclopropylcarboxamide |  | Reverse Mutation | <i>E.coli</i> WP2 <i>uvrA</i> <sup>1</sup>             | Up to 5000 µg/plate | Negative <sup>1</sup> | (Bowles, 2003)                       | Cytotoxic at different<br>concentration with and<br>without S9. |
|                        |   |   | Reverse Mutation | <i>S.typhimurium</i> TA97a,<br>TA1535                  | Up to 2000 µg/plate | Negative              | (Next Century<br>Incorporated, 2004) |   |
|                        |   |   | Reverse Mutation | <i>S.typhimurium</i> TA98,<br>TA100                    | Up to 5000 µg/plate | Negative              | (Next Century<br>Incorporated, 2004) |   |
|                        |   |   | Reverse Mutation | <i>Escherichia coli</i> WP2<br><i>uvrA</i> (328)       | Up to 2000 µg/plate | Negative              | (Next Century<br>Incorporated, 2004) |   |








<sup>1</sup> With and without S9.

### TABLE 3: SUMMARY OF SAFETY EVALUATIONS










Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)

| FL-no<br>JECFA-no | EU Register name   | Structural formula  | EU MSDI 1)<br>US MSDI<br>(µg/capita/day) | Class 2)<br>Evaluation procedure<br>path 3) | Outcome on the<br>named compound<br>[4) or 5)] | EFSA conclusion on the<br>named compound<br>(Procedure steps, intake<br>estimates, NOAEL,<br>genotoxicity) | EFSA conclusion on the<br>material of commerce  |
|-------------------|--------------------|---|--|---|--|--|---|
| 11.001<br>1587    | 3-Methylbutylamine |    | 24<br>0.07                               | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.002<br>1583    | Isobutylamine      |    | 0.012<br>0.09                            | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.003<br>1582    | Butylamine         |    | 89<br>0.01                               | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.004<br>1580    | Propylamine        |    | 0.012<br>0.02                            | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.005<br>1584    | sec-Butylamine     |   | 0.012<br>2                               | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | Racemate.<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach. |
| 11.009<br>1610    | Trimethylamine     |  | 130<br>70                                | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.015<br>1579    | Ethylamine         |  | 0.012<br>0.2                             | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |
| 11.016<br>1588    | Hexylamine         |  | 0.024<br>0.007                           | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.              |








**Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)**

| FL-no<br>JECFA-no | EU Register name                 | Structural formula  | EU MSDI 1)<br>US MSDI<br>( $\mu\text{g/capita/day}$ ) | Class 2)<br>Evaluation procedure<br>path 3) | Outcome on the<br>named compound<br>[4) or 5)] | EFSA conclusion on the<br>named compound<br>(Procedure steps, intake<br>estimates, NOAEL,<br>genotoxicity) | EFSA conclusion on the<br>material of commerce   |
|-------------------|----------------------------------|---|---|---|--|--|--|
| 11.018<br>1581    | Isopropylamine                   |    | 0.012<br>0.02   | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 11.020<br>1586    | 2-Methylbutylamine               |    | 0.012<br>0.02   | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | Racemate.<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 11.021<br>1585    | Pentylamine                      |    | 0.037<br>0.2  | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 11.023<br>1611    | Triethylamine                    |    | 0.073<br>0.9  | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 11.025<br>1614    | Trimethylamine oxide             |    | 2.3<br>0.09   | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 11.026<br>1612    | Tripropylamine                   |  | 0.012<br>0.02   | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 16.092<br>1602    | N,N-Dimethyl menthyl succinamide |  | 61<br>88  | Class I<br>A3: Intake below threshold       | 4)   | No safety concern at the estimated level of intake based on the MSDI approach                              | Register name to to be changed to (1R,2S,5R)-N,N-Dimethyl menthyl succinamide.<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach. |




**Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)**

| FL-no<br>JECFA-no | EU Register name              | Structural formula  | EU MSDI 1)<br>US MSDI<br>( $\mu\text{g/capita/day}$ ) | Class 2)<br>Evaluation procedure<br>path 3) | Outcome on the<br>named compound<br>[4) or 5)] | EFSA conclusion on the<br>named compound<br>(Procedure steps, intake<br>estimates, NOAEL,<br>genotoxicity)                                  | EFSA conclusion on the<br>material of commerce  |
|-------------------|-------------------------------|---|---|---|--|---|---|
| 11.006<br>1589    | Phenethylamine                |    | 0.075<br>0.05   | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at the estimated level of intake based on the MSDI approach.  |
| 11.007<br>1590    | 2-(4-Hydroxyphenyl)ethylamine |    | 0.012<br>0.02   | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 14.010<br>1607    | Piperidine                    |    | 88<br>96  | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 14.064<br>1609    | Pyrrolidine                   |    | 0.12<br>2   | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 14.080<br>1604    | 2-Acetyl-1-pyrroline          |    | 0.012<br>0.1  | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 14.133<br>1608    | 2-Methylpiperidine            |    | 0.012<br>0.002  | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | Racemate.<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.                             |
| 14.141<br>1615    | Piperazine                    |  | 0.012<br>0.002  | Class II<br>A3: Intake below threshold      | 4)   | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.  |
| 14.167<br>1603    | 1-Pyrroline                   |  | 0.012<br>0.4  | Class II<br>A3: Intake below threshold      | 4)   | EU MSDI is available<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach                   | EU MSDI is available<br>No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.                  |
| 16.049<br>1593    | Butyramide                    |  | 0.012<br>0.002  | Class II<br>A3: Intake below threshold      | 4)   | The Panel concluded that the substance cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicit | The Panel concluded that the substance cannot be evaluated through the Procedure due to concern with respect to genotoxicity/carcinogenicit |

**Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)**

| FL-no<br>JECFA-no | EU Register name                                    | Structural formula  | EU MSDI 1)<br>US MSDI<br>(µg/capita/day) | Class 2)<br>Evaluation procedure<br>path 3)                           | Outcome on the<br>named compound<br>[4) or 5)]  | EFSA conclusion on the<br>named compound<br>(Procedure steps, intake<br>estimates, NOAEL,<br>genotoxicity)  | EFSA conclusion on the<br>material of commerce   |
|-------------------|---|---|--|---|---|---|--|
| 16.013<br>1601    | N-Ethyl-2-isopropyl-5-methylcyclohexane carboxamide |    | 0.4<br>127                               | Class III<br>B3: Intake above threshold                               | Data must be available 5)<br>Data were available indicate that the substance would not be expected to raise safety concern. | y<br>Additional data indicate that the substance would not be expected to raise safety concerns at its estimated level of intake when used as flavourings | y-<br>Composition of stereoisomeric mixture to be specified.<br>Additional data indicate that the substance would not be expected to raise safety concern at its estimated level of intake when used as flavourings. |
| 16.053<br>1595    | 2-Isopropyl- N,2,3-trimethylbutanamide              |    | 24<br>1054                               | Class III<br>B3: Intake above threshold                               | Data must be available 5)<br>Data were available indicate that the substance would not be expected to raise safety concern. | No safety concern at the estimated level of intake based on the MSDI approach. EFSA concluded at step B4: Yes, an adequate NOAEL could be established     | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 11.014<br>1613    | N,N-Dimethylphenethylamine                          |    | 0.012<br>0.09                            | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL exists | 4)  | Additional toxicity data required   | Additional toxicity data required.<br>Name to be changed to (R)-N,N-Dimethylphenethylamine.  |
| 11.017<br>1606    | N-Isopentylidene isopentylamine                     |    | 0.012<br>0.01                            | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL exists | 4)  | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 14.003<br>1600    | Piperine  |  | 20<br>0.07                               | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL exists | 4)  | Additional toxicity data required   | CASrn in the Register refers to the trans, trans isomer<br>Register name to be changed to (E,E)-piperidine.<br>Additional toxicity data required.  |
| 16.006<br>1599    | N-Nonanoyl 4-hydroxy-3-methoxybenzylamide           |  | 6.0<br>0.07                              | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL exists | 4)  | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |
| 16.052<br>1594    | 1,6-Hexalactam                                      |  | 0.012<br>0.002                           | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL exists | 4)  | No safety concern at the estimated level of intake based on the MSDI approach   | No safety concern at estimated level of intake as flavouring substance based on the MSDI approach.   |

**Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)**

| FL-no<br>JECFA-no | EU Register name                             | Structural formula  | EU MSDI 1)<br>US MSDI<br>( $\mu\text{g/capita/day}$ ) | Class 2)<br>Evaluation procedure<br>path 3)                              | Outcome on the<br>named compound<br>[4) or 5)] | EFSA conclusion on the<br>named compound<br>(Procedure steps, intake<br>estimates, NOAEL,<br>genotoxicity) | EFSA conclusion on the<br>material of commerce |
|-------------------|--|---|---|--|--|--|--|
| 16.091<br>1598    | Deca-(2E,4E)-dienoic acid isobutyl-<br>amide |  | 6.1<br>83   | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL<br>exists | 4)   | Additional toxicity data<br>required   | Additional toxicity data<br>required.          |
| 16.093<br>1597    | N-Cyclopropyl (2E,6Z)-<br>nonadienamide      |  | 61<br>40  | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL<br>exists | 4)   | Additional toxicity data<br>required   | Additional toxicity data<br>required.          |
| 16.094<br>1596    | N-Ethyl (2E,6Z)-nonadienamide                |  | 61<br>88  | Class III<br>B3: Intake below threshold,<br>B4: Adequate NOAEL<br>exists | 4)   | Additional toxicity data<br>required   | Additional toxicity data<br>required.          |

- 1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) =  $\mu\text{g/capita/day}$ .
- 2) Thresholds of concern: Class I = 1800  $\mu\text{g/person/day}$ , Class II = 540  $\mu\text{g/person/day}$ , Class III = 90  $\mu\text{g/person/day}$ .
- 3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
- 4) No safety concern based on intake calculated by the MSDI approach of the named compound.
- 5) Data must be available on the substance or closely related substances to perform a safety evaluation.

## REFERENCES

- Adler ID, Ingwersen I, 1989. Evaluation of chromosomal aberrations in bone marrow of 1C3F1 mice. *Mutat. Res.* 224, 343-345.
- Andrews AW, Fornwald JA and Lijinsky W, 1980. Nitrosation and mutagenicity of some amine drugs. *Toxicol. Appl. Pharmacol.* 52, 237-244.
- Bempong MA and Scully Jr FE, 1983. Seminal cytology and reproductive toxicology of N-chloropiperidine. *J. Am. Coll. Toxicol.* 2, 209-219.
- Bhat BG and Chandrasekhara N, 1986b. Lack of adverse influence of black pepper, its oleoresin and piperine in the weanling rat. *J. Food Saf.* 7, 215-223.
- Bowles AJ, 2003. Reverse mutation assay (ames-test) using *Salmonella typhimurium* and *Escherichia coli*. SafePharm Laboratories Ltd., Shardlow, United Kingdom. Project No. 1543/077. Unpublished report submitted by EFA to FLAVIS Secretariat.
- Cheng MC, 1982. A subchronic oral toxicity study of T0332.04 in rats. Sugy No. 80063, Vol. 1 Hazleton Laboratories, Madison, Wisconsin, USA. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- Chieli E, Aliboni F, Saviozzi M and Malvaldi G, 1987. Induction of micronucleated erythrocytes by primary thioamides and their metabolites in the mouse. *Mutat. Res.* 192, 141-143.
- Clay P, 2003. Nonivamide (PAVA) *In-vivo* rat liver Unscheduled DNA Synthesis assay. Central Toxicology Laboratory report CTL/SR1166, 13 June 2003.
- COT, 2002. COT (non food) statement on the use of PAVA (Nonivamide) as an incapacitant spray. Committee on Toxicity, April 2002.
- COT, 2004. COT Statement on the use of PAVA (Nonivamide) as an incapacitant spray. Committee on Toxicity, November 2004.
- Danz M and Urban H, 1979. Carcinogens, promoters and suspicious drugs: Their identical short-term effect in a promoting activity test (PAT). *Experimentelle Pathologie* 17, 181-184.
- Daware MB, Mujumdar AM and Ghaskadbi S, 2000. Reproductive toxicity of piperine in swiss albino mice. *Planta Med.* 66, 231-236.
- EC, 1996a. Regulation No 2232/96 of the European Parliament and of the Council of 28 October 1996. *Official Journal of the European Communities* 23.11.1996, L 299, 1-4.
- EC, 1999a. Commission Decision 1999/217/EC of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs. *Official Journal of the European Communities* 27.3.1999, L 84, 1-137.
- EC, 2000a. Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation programme in application of Regulation (EC) No 2232/96. *Official Journal of the European Communities* 19.7.2000, L 180, 8-16.



- EC, 2009a. Commission Decision 2009/163/EC of 26 February 2009 amending Decision 1999/217/EC as regards the Register of flavouring substances used in or on foodstuffs. Official Journal of the European Union 27.2.2009, L 55, 41.
- EFFA, 2004ao. EFFA Poundage Survey 2004: European inquiry on volume use. Private communication to the Flavor and Extract Manufacturers Association (FEMA) and the International Organization of the Flavor Industry (IOFI). Unpublished data.
- EFFA 2005c. Submission 2004-19 +2004-33. Assessment of 37 Flavouring Substances of the Chemical Groups 19 and 33 (Annex I of 1565/2000/EC), Aliphatic and Aromatic Amines and Amides [FEMA 2005-7] Used as Flavouring Substances.4 April 2005. Unpublished report submitted by EFFA to FLAVIS Secretariat. FLAVIS/8.42.
- EFFA, 2007a. E-mail from Jan Demyttenaere, EFFA to Flavis Secretariat, National Foodinstitute, Technical University of Denmark. Dated 8 February 2007. RE: FLAVIS submissions - use levels for Category 14.2 - Alcoholic beverages FLAVIS/8.70.
- EFFA, 2010a. EFFA Letters to EFSA for clarification of specifications and isomerism for which data were requested in published FGEs.
- EFSA, 2004d. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to Flavouring Group Evaluation 03: Acetals of branched- and straight-chain aliphatic saturated primary alcohols and branched- and straight-chain saturated aldehydes, and an orthoester of formic acid, from chemical groups 1 and 2 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 7 October 2004. EFSA-Q-2003-146.
- EFSA, 2008b. Minutes of the 26<sup>th</sup> Plenary meeting of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food, Held in Parma on 27 - 29 November 2007. Parma, 7 January 2008. [Online]. Available: [http://www.efsa.europa.eu/EFSA/Event\\_Meeting/afc\\_minutes\\_26thplen\\_en.pdf](http://www.efsa.europa.eu/EFSA/Event_Meeting/afc_minutes_26thplen_en.pdf)
- EFSA, 2008e. Minutes of the 30<sup>th</sup> Plenary meeting of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food, Held in Parma on 20-22 May 2008. Parma, 9 July 2008. [Online]. Available: [http://www.efsa.europa.eu/cs/BlobServer/Event\\_Meeting/afc\\_minutes\\_30thplen\\_en.pdf?ssbinary=true](http://www.efsa.europa.eu/cs/BlobServer/Event_Meeting/afc_minutes_30thplen_en.pdf?ssbinary=true)
- EFSA, 2010aj. Opinion of the Scientific Panel on contact Materials, Enzymes, Flavourings and Processing Aids on a request from Commission related to Flavouring Group Evaluation 96 (FGE.96), addendum to FGE. 50, 51, 52, 53, 54, 56, 58, 59, 61, 62, 63, 64, 66, 68, 69, 70, 71, 73, 76, 77, 79, 80, 83, 84, 85, 86 and 87: Consideration of 102 flavouring substances considered by EFSA for which EU production volumes / anticipated production volumens have been submitted on request by DG SANCO (Commission Regulation (EC) No 1565/2000 of 18 July 2000).
- EFSA, 2010i. Opinion of the Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids on a request from the Commission related to Flavouring Group Evaluation 94 (FGE.94): Consideration of aliphatic amines and amides evaluated in addendum to the JECFA group aliphatic and aromatic amines and amides by JECFA (68th meeting) (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 23 September 2009. EFSA-Q-2009-00560.
- Fahrig R, 1989. Possible recombinogenic effect of caprolactam in the mammalian spot test. Mutat. Res. 224, 373-375.
- Flavour Industry, 2004e. Unpublished information submitted by Flavour Industry to DG SANCO and forwarded to EFSA. A-86.

- Flavour Industry, 2004f. Unpublished information submitted by Flavour Industry to DG SANCO and forwarded to EFSA. A-86.
- Florin I, Rutberg L, Curvall M and Enzell CR, 1980. Screening of tobacco smoke constituents for mutagenicity using the Ames' test. *Toxicology*. 18, 219-232.
- Gage JC, 1970. The subacute inhalation toxicity of 109 industrial chemicals. *Br. J. Ind. Med.* 27(1), 1-18.
- Garberg P, Aakerblom E-L and Bolcsfoldi G, 1988. Evaluation of a genotoxicity test measuring DNA-strand breaks in mouse lymphoma cells by alkaline unwinding and hydroxyapatite elution. *Mutat. Res.* 203(3), 155-176.
- Green NR and Savage JR, 1978. Screening of safrole, eugenol, their ninhydrin positive metabolites and selected secondary amines for potential mutagenicity. *Mutat. Res.* 57, 115-121.
- Haworth S, Koo S and Lawlor T, 1978. Salmonella/mammalian-microsome plate incorporation mutagenesis assay of compound #T0332.01 (MRI #78). EG\_G Mason Research Institute, Rockville, MD. Unpublished report to the Flavor and Extract Manufacturers Association (FEMA). Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington, DC, USA.
- Haworth S, Lawlor T, Mortelmans K, Speck W and Zeiger E, 1983. Salmonella mutagenicity test results for 250 chemicals. *Environ. Mutag.* 5 (Suppl. 1) 3-142.
- Hellmér L and Bolcsfoldi G, 1992a. An evaluation of the *E. coli* K-12 uvrB/recA DNA repair host-mediated assay. *In vitro* sensitivity of the bacteria to 61 compounds. *Mutat. Res.* 272, 145-160.
- James R, 1974. Appendix 4, animal studies-summary of results. N-Ethyl-2-isopropyl-5-methylcyclohexane. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- JECFA, 1995. Evaluation of certain food additives and contaminants. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food Additives. 14-23 February 1995. WHO Technical Report Series, no. 859. Geneva.
- JECFA, 1996a. Toxicological evaluation of certain food additives. The forty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives and contaminants. WHO Food Additives Series: 35. IPCS, WHO, Geneva.
- JECFA, 1997a. Evaluation of certain food additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva, 6-15 February 1996. WHO Technical Report Series, no. 868. Geneva.
- JECFA, 1999b. Evaluation of certain food additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. Rome, 17-26 June 1997. WHO Technical Report Series, no. 884. Geneva.
- JECFA, 2005d. Compendium of food additive specifications. Addendum 13. Joint FAO/WHO Expert Committee of Food Additives 65<sup>th</sup> session. Geneva, 7-16 June 2005. FAO Food and Nutrition paper 52 Add. 13.
- JECFA, 2006b. Evaluation of certain food additives. Sixty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, no. 934. Geneva, 7-16 June 2005.
- JECFA, 2006c. Joint FAO/WHO Expert Committee on Food Additives. Sixty-seventh meeting. Rome, 20-29 June 2006, Summary and Conclusions. Issued 7 July 2006.

- JECFA, 2006d. Safety evaluation of certain food additives and contaminants. Sixty-fifth meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 56. IPCS, WHO, Geneva.
- JECFA, 2009c. Evaluation of certain food additives. Sixty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, no. 952. Rome, 17-26 June 2008. [http://whqlibdoc.who.int/trs/WHO\\_TRS\\_952\\_eng.pdf](http://whqlibdoc.who.int/trs/WHO_TRS_952_eng.pdf) (May 2009)
- Karekar VR, Mujumdar AM, Joshi SS, Dhuley J, Shinde SL and Ghaskadbi S, 1996. Assessment of genotoxic effect of piperine using *Salmonella typhimurium* and somatic and germ cells of Swiss albino mice. *Arzneim.-Forsch./Drug Res.* 46(10), 972-975.
- King MT, 2003. Mutagenicity study of HR 03/G05015 in the *Salmonella typhimurium*/mammalian microsome reverse mutation assay (Ames-test). Project No. AM00103N. King & Harnasch GmbH. Unpublished report to the Flavor and Extract Manufacturers Association (FEMA). Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington, DC, USA.
- Kirby PE, Branch ML and Pizzarello RF, 1978. L5178Y Mouse lymphoma mutagenesis assay of compound #T0332.01 (MRI #78). EG\_G Mason Research Institute, Rockville, MD. Unpublished report to the Flavor and Extract Manufacturers Association (FEMA). Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington, DC, USA.
- Lynch DW, Moorman TR, Lewis TR, Stober P, Hamlin RD and Schueler RL, 1990. Subchronic inhalation of triethylamine vapor in Fischer F344 rats: organ system toxicity. *Toxicol. Ind. Health.* 6, 403-414.
- McGregor DB, Riach CG, Brown A, Edwards I, Reynolds D, West K and Willington S, 1988c. Reactivity of catecholamines and related substances in the mouse lymphoma L5178Y cell assay for mutagens. *Environ. Mol. Mutat.* 11(4), 523-544.
- Mirkova ET, 1996. Activities of the rodent carcinogens thioacetamide and acetamide in the mouse bone marrow micronucleus assay. *Mutat. Res.* 352, 23-30.
- Miyagawa M, Takasawa H, Sugiyama A, Inoue Y, Murata T, Uno Y and Yoshikawa K. 1995. The *in vivo-in vitro* replicative DNA synthesis (RDS) test with hepatocytes prepared from male B6C3F1 mice as an early prediction assay for putative nongenotoxic (Ames-negative) mouse hepatocarcinogens. *Mutat. Res.* 343, 157-183.
- Miyata K, 1995. Summary of 28-day repeated dose oral toxicity study of WS-3. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- Moore GE, 2002. 28-dietary toxicity study in rodents. Study No. 11326. Product Safety Labs, East Brunswick, New Jersey, USA. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- Morita T, Asano N, Awogi T, Sasaki YF, Sato S, Shimada H, Sutou S, Suzuki T, Wakata A, Sofuni T and Hayashi M, 1997. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6<sup>th</sup> collaborative study by CSGMT/JEMS \* MMS. *Mutat. Res.* 389, 3-122.
- Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B and Zeiger E, 1986. *Salmonella* mutagenicity tests II. Results from the testing of 270 chemicals. *Environ. Mol. Mutag.* 8(Suppl. 7), 1-119.

- Muralidhara and Narasimhamurthy K, 1990. Lack of genotoxic effects of piperine, (the active principle of black pepper) in albino mice. *J. Food Saf.* 11, 39-48.
- Neuhäuser-Klaus A and Lehmacher W, 1989. The mutagenic effect of caprolactam in the spot test with (T x HT)F1 mouse embryos. *Mutat. Res.* 224, 369-371.
- Next Century Incorporated, 2004. Proprietary protection. 04-237: Bacterial reverse mutation test: plate incorporation and preincubation method for solids. Stirparo, B.S. Project no. 04-09-006. December 1, 2004. Unpublished report submitted by EFFA to FLAVIS Secretariat.
- Nixon G and Alden C, 1978. 14-Day pilot intubation study (YE-193; TGSE-1540; P78-045). Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- NTP, 1982a. Carcinogenesis Bioassay of Caprolactam (CAS no. 105-60-2) F344 Rats and B6C3F1 Mice (Feed Study), TR 214.
- Ohshima H, Friesen M, Malaveille C, Brouet I, Hautefeuille A and Bartsch H, 1989. Formation of direct-acting genotoxic substances in nitrosated smoked fish and meat products: Identification of simple phenolic precursors and phenyldiazonium ions as reactive products. *Food Chem. Toxicol.* 27(3), 193-203.
- Pence DH, 1980a. Subchronic oral toxicity study in rats. T-0332.03. Hazleton Laboratories, Falls Church, Virginia, USA. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- Pence DH, 1980b. Reproduction and teratology study i rats. T-0332.03. Final report. Hazleton Laboratories, Falls Church, Virginia, USA. Unpublished report to the Flavor Manufacturers Association. Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington DC, USA.
- Posternak NM, Linder A and Vodoz CA, 1969. Summaries of toxicological data. Toxicological tests on flavouring matters. *Food Cosmet. Toxicol.* 7, 405-407.
- Sasaki YF, Sekihashi K, Izumiyama F, Nishidate E, Saga A, Ishida K and Tsuda S, 2000. The comet assay with multiple mouse organs: comparision of comet assay results and carcinoginecity with 208 chemicals selected from the IARC monographs and U.S. NTP carcinogenicity database. *Crit. Rev. Toxicol.* 30(6), 629-799.
- SCF, 1999a. Opinion on a programme for the evaluation of flavouring substances (expressed on 2 December 1999). Scientific Committee on Food. SCF/CS/FLAV/TASK/11 Final 6/12/1999. Annex I the minutes of the 119<sup>th</sup> Plenary meeting. European Commission, Health & Consumer Protection Directorate-General.
- SCF, 2002h. Opinion of the Scientific Committee on Food on Capsaicin (adopted on 26 February 2002). Scientific Committee on Food. SCF/CS/FLAVOUR/8 ADD1 Final. 28 February 2002. European Commission, Health & Consumer Protection Directorate-General.
- Sina JF, Bean CL, Dysart GR, Taylor VI and Bradley MO 1983. Evaluation of the alkaline elution/rat hepatocyte assay as a predictor of carcinogenic/mutagenic potential. *Mutat. Res.* 113, 357-391.
- Skinner WA, 1978. Unscheduled DNA synthesis assay of Procter & Gamble compound #T0332.01. SRI International, Menlo Park, CA. EGeG Mason Research Institute, Rockville, MD. Unpublished report to the Flavor and Extract Manufactures Association (FEMA). Submitted to WHO by the Flavor and Extract Manufacturers Association of the United States, Washington, DC, USA.

- Uno Y, Takasawa H, Miyagawa M, Inoue Y, Murata T and Yoshikawa, K, 1994. An *in vivo-in vitro* replicative DNA synthesis (RDS) test using rat hepatocytes as an early prediction assay for nongenotoxic hepatocarcinogens screening of 22 known positives and 25 noncarcinogens. *Mutat. Res.* 320, 189-205.
- Vogel EW, 1989. Caprolactam induces genetic alterations in early germ cell stages and in somatic tissue of *D. melanogaster*. *Mutat. Res.* 224, 339-342.
- Wangenheim J and Bolcsfoldi G, 1988. Mouse lymphoma L5178Y thymidine kinase locus assay of 50 compounds. *Mutagenesis* 3(3), 193-205.
- Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K and Speck W, 1987. Salmonella mutagenicity tests. 3. Results from the testing of 255 chemicals. *Environ. Mol. Mutag.* 9(Suppl. 9), 1-110.

## ABBREVIATIONS

|             |   |
|-------------|---|
| BW          | Body Weight   |
| CAS         | Chemical Abstract Service   |
| CEF         | Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids |
| CHO         | Chinese hamster ovary (cells)   |
| CoE         | Council of Europe   |
| COT         | Committee on Toxicity of Chemicals in Food                                |
| DMSO        | Dimethyl Sulphoxide   |
| DNA         | Deoxyribonucleic acid   |
| EFSA        | The European Food Safety Authority  |
| EPA         | United States Environmental Protection Agency                             |
| EU          | European Union  |
| FAO         | Food and Agriculture Organization of the United Nations                   |
| FEMA        | Flavor and Extract Manufacturers Association                              |
| FGE         | Flavouring Group Evaluation   |
| FLAVIS (FL) | Flavour Information System (database)                                     |
| GLP         | Good laboratory practice  |
| ID          | Identity  |
| Ip          | Intraperitoneal   |
| IR          | Infrared spectroscopy   |
| JECFA       | The Joint FAO/WHO Expert Committee on Food Additives                      |
| MSDI        | Maximised Survey-derived Daily Intake                                     |
| mTAMDI      | Modified Theoretical Added Maximum Daily Intake                           |
| NCE         | Normochromatic erythrocyte  |
| No          | Number  |
| NOAEL       | No observed adverse effect level  |
| NOEL        | No observed effect level  |
| NTP         | National Toxicology Program   |
| PCE         | Polychromatic erythrocyte   |

---

|     |                              |
|-----|------------------------------|
| SCE | Sister chromatic exchange    |
| SCF | Scientific Committee on Food |
| WHO | World Health Organisation    |